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Abstract
Antibody diversity is generated through the random recombination of immunoglobulin gene segments. As a
consequence of this stochastic process, antibodies recognizing self-antigens can also be produced. Continued
antibody gene rearrangement, termed receptor editing, is an important mechanism of central B cell tolerance
that serves to alter the antibody specificity of developing B cells. Although it has been demonstrated to be
critical for normal B cell development, the role of receptor editing in the context of autoimmune disease and
the forces that stimulate receptor editing are not fully understood. To address these issues, a novel quantitative
assay based upon Recombining Sequence (RS) recombination was developed to measure receptor editing
rearrangements in B cell populations. RS rearrangement is a recombination of a non-coding gene segment in
the immunoglobulin κ light chain locus. Unlike other markers of receptor editing, the RS rearrangement assay
does not rely upon expressed components of the B cell receptor and therefore is not restricted to specific
autoantigens.
As receptor editing may be defective in some autoimmune individuals, the RS assay was applied to
autoimmune mouse models of systemic lupus erythematosus (SLE) and type 1 diabetes (T1D), which
demonstrated decreased receptor editing levels relative to wild-type mice. Low RS rearrangement levels were
also observed in human subjects with SLE or T1D, suggesting that defects in receptor editing may contribute
to disease susceptibility. Additionally, RS rearrangement was used to assess the role of self-antigen mediated B
cell signaling in the stimulation of receptor editing. B cells expressing an anti-DNA heavy chain were found to
undergo more extensive receptor editing and functional precursors of editing were found to be biased towards
autoreactivity, indicating that self-reactivity may promote receptor editing. To begin to examine whether
positive signaling is required for receptor editing, the roles of the inhibitory kinase Lyn and a disease
associated variant of the lymphoid phosphatase PTPN22 were analyzed. The results indicate that aberrant
activity of these signaling components alone does not influence receptor editing. Collectively the findings
described in this dissertation demonstrate that RS rearrangement is an effective means of estimating receptor
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RS REARRANGEMENT: OBSERVATIONS AND IMPLICATIONS FROM A 
NOVEL ASSAY OF B CELL TOLERANCE 
 
Anil K. Panigrahi 
 
Eline T. Luning Prak 
 
Antibody diversity is generated through the random recombination of 
immunoglobulin gene segments.  As a consequence of this stochastic process, 
antibodies recognizing self-antigens can also be produced.  Continued antibody gene 
rearrangement, termed receptor editing, is an important mechanism of central B cell 
tolerance that serves to alter the antibody specificity of developing B cells.  Although it 
has been demonstrated to be critical for normal B cell development, the role of receptor 
editing in the context of autoimmune disease and the forces that stimulate receptor 
editing are not fully understood.  To address these issues, a novel quantitative assay 
based upon Recombining Sequence (RS) recombination was developed to measure 
receptor editing rearrangements in B cell populations.  RS rearrangement is a 
recombination of a non-coding gene segment in the immunoglobulin κ light chain 
locus.  Unlike other markers of receptor editing, the RS rearrangement assay does not 
rely upon expressed components of the B cell receptor and therefore is not restricted to 
specific autoantigens. 
As receptor editing may be defective in some autoimmune individuals, the RS 
assay was applied to autoimmune mouse models of systemic lupus erythematosus (SLE) 
and type 1 diabetes (T1D), which demonstrated decreased receptor editing levels 
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relative to wild-type mice.  Low RS rearrangement levels were also observed in human 
subjects with SLE or T1D, suggesting that defects in receptor editing may contribute to 
disease susceptibility.  Additionally, RS rearrangement was used to assess the role of 
self-antigen mediated B cell signaling in the stimulation of receptor editing.  B cells 
expressing an anti-DNA heavy chain were found to undergo more extensive receptor 
editing and functional precursors of editing were found to be biased towards 
autoreactivity, indicating that self-reactivity may promote receptor editing.  To begin to 
examine whether positive signaling is required for receptor editing, the roles of the 
inhibitory kinase Lyn and a disease associated variant of the lymphoid phosphatase 
PTPN22 were analyzed.  The results indicate that aberrant activity of these signaling 
components alone does not influence receptor editing.  Collectively the findings 
described in this dissertation demonstrate that RS rearrangement is an effective means 
of estimating receptor editing that may be used to monitor B cell central tolerance and 
further evaluate the regulation of editing rearrangement. 
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In order to recognize the vast array of antigens encountered by the immune 
system, B cells undergo a stochastic process of gene rearrangement to generate a 
diverse repertoire of unique receptors.  Immunoglobulin gene rearrrangement, also 
termed V(D)J recombination, is highly regulated to ensure the efficient generation of B 
cells that carry multiple copies a single B cell receptor.  Due to the random nature of this 
process, an inevitable consequence is the production of self-reactive B cells.  In 
response to the development of autoreactive B cells, tolerance checkpoints exist at 
several stages of B cell development to remove or alter these cells and thereby prevent 
the development of autoimmunity.  In this chapter I will begin with a brief review of B 
cell development and will follow with a discussion of the regulation of immunoglobulin 
gene rearrangement, highlighting key regulatory mechanisms that act both genetically 
and at the protein level.  Finally, the chapter will conclude with a discussion of the 
prevalence of autoreactive B cells and the immunological tolerance mechanisms that 
serve to silence them. 
 
B Cell Development 
B cells develop from hematopoietic stem cells through a series of differentiative 
steps.  During fetal and neonatal life murine B cell development begins in the liver with 
the generation of B1a B cells (Hayakawa et al. 1985).  These B cells, which are IgMhi IgDlo 
CD11b+ CD5+ (Dorshkind and Montecino-Rodriguez 2007), normally populate the 
pleural and peritoneal cavities and express a limited repertoire of immunoglobulin 
genes (Yancopoulos et al. 1988).  The restricted use of DH-proximal VH genes results in 
a decreased ability of B1a cells to respond to diverse antigens.  However, B1a B cells 
have been shown to secrete “natural antibodies” which are mainly of the IgM isotype and 
are polyreactive, recognizing common bacterial and viral antigens as well as self-
antigens (Hayakawa et al. 1984; Hayakawa et al. 2003).  Consequently, B1a B cells have 
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been proposed to function as links between innate and adaptive immune responses by 
providing a quickly activated non-specific humoral response. 
In mature mice, B cell development takes place in the bone marrow where 
hematopoietic stem cells (HSCs) gradually lose their ability to form other cell types and 
become committed to a B cell fate (Fig. 1-1).  Multipotent progenitors (MPPs) are the 
most HSC-proximal cell type to show evidence of B lineage specification with a subset of 
MPPs expressing the RAG1 and RAG2 genes (Igarashi et al. 2002; Rumfelt et al. 2006).  
MPPs then give rise to common lymphoid progenitors (CLPs) which act as a key source 
of B-lineage committed cells.  CLPs express high levels of B cell specific genes and are 
the earliest cell type to express the IL-7 receptor, marking this as a critical stage in B 
cell development (Miller et al. 2002).  CLPs generate pre-pro B cells (Hardy fraction A) 
that are CD45R/B220+ (hereafter B220) but lack CD19 expression.  The vast majority of 
these cells (~75%) carry DHJH rearrangements on both alleles and express high levels of B 
cell transcription factors Pax5 and EBF (Li et al. 1996), indicating their high degree of B 
cell commitment.  Expression of Pax5 and EBF activates the B cell transcriptional 
program in earnest leading to development of pro-B cells (Hardy fraction B) that are fully 
committed to the B lineage (Nutt et al. 1999; Pongubala et al. 2008).  Fraction (Fr.) B 
pro-B cells lead to early pre-B cells (Hardy Fr. C) which complete VH to DHJH 
rearrangement and assemble the pre-B cell receptor (pre-BCR) at the cell surface (Hardy 
et al. 1991; Nishimoto et al. 1991).  Signaling via the pre-BCR results in several rounds 
of cell division as well as pre-BCR downregulation via a negative-feedback loop (Mundt 
et al. 2001; Parker et al. 2005).  Following proliferation, late pre-B cells (Hardy Fr. D), 
which no longer express surface immunoglobulin, commence light chain gene 
rearrangement.  Productive light chain rearrangement leads to light chain expression 
and assembly of the B cell receptor (BCR) on the surface of immature B cells (Hardy Fr. 
E).  These newly formed immature B cells can continue development in the bone marrow 
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(Lindsley et al. 2007) or transit to the spleen where they continue development as 
transitional B cells (Loder et al. 1999). 
Although there is increasing evidence for the maturation of transitional B cells in 
the bone marrow (Cariappa et al. 2007), B cell maturation has been more rigorously 
characterized in the periphery where transitional B cells have been defined in multiple 
developmental schemes (Loder et al. 1999; Allman et al. 2001).  In this dissertation I will 
use the stages described by Allman et al., which separate transitional B cells into three 
distinct subsets, T1, T2, and T3.  B cells in all three transitional subsets demonstrate 
characteristics of immaturity including failure to proliferate in response to BCR 
signaling, rapid turnover rate, and expression of the cell surface marker CD93/AA4 
(Rolink et al. 1998; Allman et al. 2001).  The T1 subset represents the least mature 
population of transitional cells as demonstrated by the absence of CD23 and IgD 
expression.  Adoptive transfer and BrdU labeling studies indicate that T1 cells give rise 
to T2 cells which begin to express both CD23 and IgD (Loder et al. 1999; Allman et al. 
2001).  The T3 subset has been proposed as an intermediate stage between T2 
transitional cells and mature B cells.  Similar to mature B cells, T3 B cells express lower 
levels of surface IgM, however, they still retain CD93/AA4 expression marking their 
immaturity.  Studies by Cambier and colleagues have suggested that the T3 subset is 
enriched for autoreactive B cells that have entered an anergic state (Merrell et al. 2006).  
These cells were found to be unresponsive to BCR stimulation as measured by 
intracellular Ca2+ levels and protein tyrosine phosphorylation (Cooke et al. 1994; 
Benschop et al. 2001). 
After progressing through transitional stages, mature B cells ultimately enter one 
of two mature splenic B cell populations.  Most developing cells enter the follicular (Fo) 
pool of mature cells which are so termed due to their location in follicles within 
peripheral lymphoid organs.  These fully mature cells exist in a resting state for 15-20 
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weeks (Rolink et al. 1998) and are found primarily in the spleen, but also circulate in the 
blood and lymph.  Rajewsky and colleagues demonstrated that survival of these cells is 
dependent upon BCR signaling (Lam et al. 1997; Kraus et al. 2004), however, the nature 
of this signal as tonic, basal signaling or antigen-dependent positive selection remains 
unresolved. 
Marginal zone (MZ) B cells comprise the second group of mature B cells that, 
unlike Fo B cells, do not circulate and instead reside primarily in regions surrounding 
marginal sinuses in the spleen.  These sinuses act as a major site of blood filtration and 
antigen presentation, thus making MZ B cells uniquely positioned to act in a primary 
response to blood borne pathogens.  Indeed, MZ B cells, much like B1 B cells, express a 
restricted repertoire of BCRs that are biased toward recognition of bacterial cell wall 
components, such as phosphorylcholine (Martin and Kearney 2000), and rapidly 
proliferate and differentiate into IgM-secreting plasmablasts in response to 
lipopolysaccharide stimulation (Oliver et al. 1999; Martin et al. 2001).  The recruitment 
of newly formed B cells into the marginal zone population is still not well characterized.  
Based on BCR repertoire bias as well as the finding of preferential recruitment of 
autoreactive B cells to the marginal zone (Martin and Kearney 2000; Li et al. 2002), it 
has been proposed that weakly self-reactive or poly-reactive B cells are selected into the 
MZ through interactions with self-antigen (Hayakawa et al. 1999; Dammers et al. 2000).  
Whether this is the primary pathway of MZ B cell development is still unclear. 
 
Regulation of V(D)J Recombination 
In order to generate competent B cells, B cell development is regulated at several 
checkpoints.  An important area of B cell regulation involves control of V(D)J 
recombination which is responsible for generating functional BCRs.  Both the BCR and 
the T cell receptor (TCR) are produced via rearrangement of gene segments in the µ, κ, 
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λ; and α, β, γ, δ loci, respectively.  Recombination of these gene segments is catalyzed 
by a protein complex that includes the lymphocyte-specific gene products of 
recombinase activating genes 1 and 2 (RAG1 and RAG2).  The RAG proteins combine to 
form a heteromultimeric complex that creates double strand DNA breaks at precise 
locations flanking immunoglobulin gene segments marked by conserved recombination 
signal sequences (RSSs).  These breaks are then resolved by additional components of 
the RAG complex which are common to the non-homologous end-joining (NHEJ) repair 
pathway (Taccioli et al. 1993; Taccioli et al. 1994; Blunt et al. 1995). 
As the RAG genes are the primary component of the recombinase machinery 
restricted to lymphocytes, they are highly regulated to ensure that V(D)J recombination 
is limited to these cells.  Furthermore, RAG expression varies throughout development, 
providing an additional level of control over gene rearrangement.  As discussed above, 
the RAG proteins are first expressed in a subset of MPPs and levels continue to rise as 
the cells develop into pro-B cells (Hardy Fr. B) where immunoglobulin heavy chain (IgH) 
gene recombination begins.  Successful V(D)J rearrangement yields an IgH variable 
region with an intact reading frame and assembly of a complete IgH that is capable of 
pairing with the surrogate light chain (SLC) and forming the pre-B cell receptor (pre-
BCR).  Surface expression of the pre-BCR results in down-regulation of RAG 
transcription and cessation of further rearrangement (Grawunder et al. 1995).  Pre-B 
cells then undergo a proliferative burst after which RAG is re-expressed and 
immunoglobulin light chain rearrangement (IgL) begins.  Generation of a functional IgL 
and assembly of the BCR on the cell surface ultimately leads to termination of RAG 
expression and gene rearrangement in immature B cells.  Thus RAG expression is 
restricted to developmental stages during which V(D)J recombination occurs.  This 
regulation occurs via transcriptional and post-transcriptional mechanisms. 
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The RAG1 and RAG2 genes are each expressed from single exons that are 
convergently transcribed.  Promoter elements for both genes have been characterized in 
mouse and man (Fuller and Storb 1997; Zarrin et al. 1997).  Although the RAG1 
promoter appears to be active in non-lymphoid cells, RAG2 promoter activity is 
lymphoid restricted (Lauring and Schlissel 1999).  Several transcription factors have 
been proposed to bind RAG promoters and enhance their activity, including c-myb and 
Pax5 (Kishi et al. 2002), lymphoid enhancer binding factor-1 (LEF-1; (Jin et al. 2002)), 
and NF-Y (Brown, Miranda et al. 1997).  Furthermore, B and T cells display differential 
RAG2 promoter binding, with Pax5 and GATA3 binding in B and T cells, respectively. 
In addition to the promoter regions, distal regulatory elements have also been 
found to modify RAG expression.  Studies using BAC reporter constructs and embryonic 
stem cell transfection assays demonstrated that RAG expression in developing B and T 
cells was independent of sequences 5’ of RAG1, but required sequences within 10kb 5’ 
of the RAG2 promoter (Monroe et al. 1999; Yu et al. 1999).  Additional reports have 
characterized several enhancers that have been shown to activate RAG expression in 
immature lymphoid cells.  The RAG locus enhancer D3, located ~8kb 5’ of the RAG2 
gene, contains binding sites for several lymphoid transcription factors, including c-myb, 
c/EBP, GATA3, and NF-κB, and was shown to activate expression in pre-T and pre-B 
cells but have minimal activity in mature lymphocytes and non-lymphoid cells (Wei et al. 
2002).  Another enhancer element, ERAG, located 22kb 5’ of the RAG2 promoter, has 
been shown to regulate RAG expression in B cells specifically.  ERAG activated RAG 
expression in pro-B cell lines and targeted deletion resulted in a partial block in B cell 
development at the pro-B cell stage (Hsu et al. 2003).  Interestingly, T cell development 
was unaffected suggesting that ERAG function is restricted to developing B cells. 
Although temporal and lineage regulation of RAG expression restricts V(D)J 
recombination to lymphocytes at specific stages in development, these mechanisms 
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cannot account for the locus preference observed in these various cell types.  For 
instance, in B cells recombination is limited to immunoglobulin genes, while TCR genes 
rearrange in T cells.  Furthermore, these rearrangements are ordered such that IgH and 
TCRβ genes rearrange before IgL and TCRα genes in B and T cells, respectively.  It is now 
becoming evident that changes in chromatin structure contribute to this additional level 
of regulation.  The initial clues implicating chromatin modification come from early 
studies of Ig gene rearrangement that showed increased transcription levels of 
unrearranged gene segments in both the IgH (Yancopoulos and Alt 1985) and IgL 
(Schlissel and Baltimore 1989) loci that correlated with their rearrangement.  These 
findings supported a model where chromatin modifications preceded gene 
rearrangement making the loci accessible, thus promoting transcription and 
rearrangement. 
DNA methylation has been proposed as a mechanism that may contribute to RAG 
substrate accessibility.  Studies of in vitro substrates have found that methylation of 
CpG dinucleotides inhibits RAG mediated cleavage of RSSs (Engler et al. 1991; Hsieh and 
Lieber 1992).  These findings were also confirmed in vivo where TCRβ recombination 
was shown to occur preferentially on hypomethylated alleles (Whitehurst et al. 2000).  
Changes in methylation that coincide with developmental patterns of V(D)J 
rearrangement have also been described.  Experiments by Bergman and colleagues 
demonstrated monoallelic demethylation of the immunoglobulin kappa (Igκ) locus in 
pre-B cells prior to rearrangement (Mostoslavsky et al. 1998).  Together these data 
support a role for DNA methylation in limiting gene rearrangement, however, more 
recent studies have questioned the validity of this model.  Induced inactivation in 
thymocytes of DNA methyltransferase 1 (Dnmt1), an enzyme responsible for adding 
methyl groups to cytosine residues, did not adversely affect the temporal pattern of TCR 
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gene rearrangement and suggests that additional methyltransferases or other regulatory 
mechanisms are involved. 
Histone modifications are a second type of chromatin mark that has been 
proposed to regulate RAG accessibility.  An indication of the importance of nucleosome 
structure in regulating V(D)J recombination came from in vitro cleavage studies of RAG 
substrates purified from different types of lymphocytes.  Schlissel and colleagues 
demonstrated that recombinant RAG was capable of cleaving RSSs from purified 
genomic DNA in a lineage-independent manner, however, DNA from nuclei of pro-B and 
pro-T cell lines only underwent rearrangement at lineage appropriate loci (Stanhope-
Baker et al. 1996).  Further studies determined that assembly of RAG substrates onto 
nucleosomes inhibited RSS cleavage indicating that changes in the chromatin landscape 
likely influence RAG accessibility (Kwon et al. 1998; Golding et al. 1999).  Consistent 
with this idea, histone acetylation and remodeling were found to enhance RAG mediated 
cleavage (Kwon et al. 2000).  Additionally, acetylation of histones was shown to be 
dynamic and correlated with developmental changes in RSS accessibility both in T and B 
cells (McMurry and Krangel 2000; Chowdhury and Sen 2001).  Interestingly, changes in 
histone acetylation have been shown to be dependent upon enhancer activity (Mathieu 
et al. 2000), providing a link between germline transcription and RAG accessibility.  
Other histone modifications are also likely involved in controlling V(D)J recombination, 
as conditional mutation of the histone methyltransferase Ezh2 inhibits VH-to-DHJH 
recombination of 5’ VH gene segments in pro-B cells and impairs their progression to 
the pre-B cell stage (Su et al. 2003). 
Despite the substantial evidence for the role of histone modifications in the 
regulation of V(D)J recombination, subsequent studies suggest that these changes alone 
are insufficient to regulate accessibility.  For instance, the decreased histone 
methylation caused by Ezh2 mutation had no effect on germline transcription and 
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histone acetylation of the IgH locus in pro-B cells (Su et al. 2003).  Moreover, 
experiments monitoring TCRβ loci stably transfected in lymphocytes found that germline 
transcription and histone acetylation were insufficient to promote recombination (Sikes 
et al. 2002).  Similar findings were observed in B cells where Pax5-/- pro-B cells failed to 
rearrange 5’ VH gene segments despite their accessibility as measured by germline 
transcription and histone acetylation (Hesslein et al. 2003).  Together these data 
indicate that although they are highly correlated with accessible chromatin, histone 
modifications alone are insufficient to regulate V(D)J rearrangement and highlight the 
multifaceted nature of recombinase regulation. 
Recent studies have introduced nuclear sublocalization as an additional 
mechanism for regulation of gene expression.  Consequently, this process has been 
studied to determine if it may contribute to regulation of V(D)J rearrangement.  Nuclear 
studies in B cells revealed that transcriptionally repressed genes co-localized with the 
lymphoid-specific transcription factor Ikaros in centromeric heterochromatin, 
suggesting a role in the lineage restriction of lymphoid gene expression (Brown, Guest 
et al. 1997).  Additional experiments revealed that in mature B cells unexpressed IgH 
and IgL alleles were associated with heterochromatin, while expressed alleles were not 
(Skok et al. 2001).  More direct evidence for the role of nuclear compartmentalization in 
the process of V(D)J recombination came from subsequent work in developing B cells.  
Kosak et al. found that in embryonic stem cells, MPPs, and pro-T cells the IgH and Igκ 
loci are positioned in the nuclear periphery, however, in pro-B cells the loci are centrally 
located (Kosak et al. 2002).  Additionally, the authors observed that once positioned 
centrally in the nucleus, the IgH locus underwent compaction that was restricted to pro-




Pre-B Cell Receptor Mediated Regulation of B Cell Development 
Expression of the pre-BCR represents another critical checkpoint in B cell 
development.  As discussed above, pre-BCR signaling serves to stop IgH recombination 
and stimulate pre-B cell proliferation.  Paradoxically, pre-BCR signaling is also involved 
in promoting IgL gene rearrangement (Lu et al. 2003; Herzog et al. 2008; Johnson et al. 
2008; Xu and Feeney 2009).  Due to the temporal proximity of these events, pre-BCR 
expression and signaling are strictly controlled in order to prevent genomic instability 
and cellular transformation.  The pre-BCR is expressed at the pre-B cell stage and is 
comprised of two IgH chains that each pair with a surrogate light chain (SLC).  The SLC 
itself is a complex of two proteins, λ5 and VpreB.  The paired IgH and SLC represent the 
extracellular components of the pre-BCR that associate with Igα and Igβ, which serve to 
propagate signals within the cell.  The requirement of pre-BCR signaling for B cell 
development was conclusively demonstrated in studies by the Rajewsky lab that 
generated mice with a targeted deletion of the transmembrane region of Igµ (IgH of 
IgM), causing disruption of its surface expression (Kitamura et al. 1991).  The loss of 
surface Igµ resulted in a block in B cell development at the pro-B stage and the absence 
of mature B cells.  Additional experiments demonstrated similar B cell developmental 
defects due to the loss of Igα and Igβ (Gong and Nussenzweig 1996; Pelanda et al. 
2002) as well as SLC components λ5 and VpreB (Kitamura et al. 1992; Mundt et al. 2001) 
indicating that signaling from the pre-BCR is critical for the pro-B to pre-B cell 
transition. 
Signaling from the pre-BCR shares several features with BCR signaling in mature 
B cells including a common signal transduction pathway (Guo et al. 2000).  However, 
although antigen binding is the stimulus for BCR signaling, it is still unclear whether 
pre-BCR signaling is ligand-dependent.  Studies using soluble pre-BCR indicated that 
that unlike BCR fragments, soluble pre-BCR readily bound to the surface of stromal cell 
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lines (Bradl and Jack 2001).  Subsequent experiments revealed that the stromal cell 
specific lectin galectin-1 directly bound the pre-BCR and was capable of initiating 
downstream tyrosine phosphorylation in pre-B cell lines (Gauthier et al. 2002), 
suggesting that interactions with stromal cells serve to activate pre-BCR signaling.  
Despite these associations, pre-B cells were found capable of proliferation and 
differentiation in vitro in the absence of supporting stromal cells (Rolink et al. 2000).  
Additionally, Monroe and colleagues observed that forced expression of Igα and Igβ 
alone was sufficient to inhibit IgH rearrangement, stimulate proliferation, and promote 
IgL recombination in pro-B cells, suggesting that pre-BCR signaling is ligand-
independent (Fuentes-Panana et al. 2004).  Ohnishi and Melchers demonstrated that an 
arginine rich portion of λ5 is required for efficient pre-BCR signaling and proposed that 
ligand-independent signaling is achieved via λ5-mediated pre-BCR internalization 
(Ohnishi and Melchers 2003), however, more recent data suggests that λ5 may in fact 
confer polyreactivity that is responsible for pre-BCR activity (Kohler et al. 2008). 
Aggregation of pre-BCRs at the cell surface is thought to promote signaling by 
bringing several downstream signal transducing factors into proximity of one another 
(Fig. 1-2).  One of the earliest factors to be recruited is the protein tyrosine kinase Syk 
(Spleen tyrosine kinase).  Syk, along with Src family kinases, such as Lyn, phosphorylates 
immunoreceptor tyrosine-based activation motifs (ITAMs) of Igα and Igβ to which it is 
then able to bind via its Src homology 2 (SH2) domains.  This association increases the 
kinase activity of Syk and promotes its autophosphorylation (Rowley et al. 1995).  Syk 
plays a significant role in driving the proliferation of pre-B cells as evidenced by the 
phenotype of Syk-/- B cells, which are developmentally arrested at the pre-B cell stage 
(Cheng et al. 1995; Turner et al. 1995).  Once activated, Syk phosphorylates the B cell 
co-receptor CD19, which in turn leads to the recruitment and activation of 
phosphoinositide 3 kinase (PI3K) (Aiba et al. 2008).  PI3K acts as part of a pathway that 
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regulates several biological processes including cell proliferation.  When activated PI3K 
phosphorylates the 3 position hydroxyl group of the inositol ring of phophatidylinositol-
4,5-bisphosphate (PIP2) located in the plasma membrane.  The resulting molecule, 
phophatidylinositol-3,4,5-triphosphate (PIP3), acts as a second messenger that recruits 
additional proteins to the plasma membrane via interactions with pleckstrin-homology 
domains.  Two such proteins are 3-phosphoinositide-dependent protein kinase 1 
(PDK1) and its target Akt, which is a primary regulator of cell proliferation (reviewed in 
(Manning and Cantley 2007)).  Thus, pre-BCR signaling promotes cell proliferation via 
the PI3K-PDK1-Akt pathway. 
In addition to driving proliferation, the PI3K-Akt signaling pathway also appears 
to be involved in inhibiting IgL rearrangement.  Clearly, preventing gene rearrangement 
during periods of multiple cell divisions is beneficial as it ensures genomic stability and 
prevents possible malignant transformation.  PI3K-Akt signaling mediates suppression 
of IgL rearrangement through interactions with the FOX class O family of transcription 
factors.  There are four members of this subgroup of transcription factors, Foxo1, 
Foxo3a, Foxo4, and Foxo6, all of which share the forkhead box DNA binding domain 
(Coffer and Burgering 2004).  Foxo3a is the dominant isoform expressed in lymphocytes 
and has been shown to regulate lymphocyte homeostasis and T cell tolerance (Lin et al. 
2004).  Foxo proteins are direct targets of Akt and when phosphorylated are removed 
from the nucleus and degraded (Biggs et al. 1999; Takaishi et al. 1999).  Recent studies 
by the Schlissel lab have revealed that Foxo1 is capable of activating transcription of 
Rag1 and Rag2 and that Akt activity decreased Rag levels in both pro-B and immature B 
cells (Amin and Schlissel 2008).  Similarly, experiments by Jumaa and co-workers 
revealed that Foxo3a activity increased Igκ expression in pre-B cells and that this effect 
could be blocked by Akt-mediated phosphorylation of Foxo3a (Herzog et al. 2008).  
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Taken together these data demonstrate the important role of the PI3K-Akt pathway in 
the regulation of pre-B cell development. 
Pre-BCR signaling is also required for initiation of IgL rearrangement (Reth et al. 
1987).  Pre-BCR regulation of IgL rearrangement appears to be highly dependent upon 
SLP65 (also known as BLNK and BASH), which may play a key role in separating 
proliferative and differentiative pre-BCR signals.  Syk-mediated phosphorylation of 
SLP65 facilitates binding of additional signaling factors to SLP65, such as Bruton’s 
tyrosine kinase (Btk) and phospholipase Cγ2 (PLCγ2), and promotes its function as a 
scaffold protein for construction of a multimeric signalosome (Koretzky et al. 2006).  
This complex has been shown to be important in regulating in IgL rearrangement both 
by downregulating pre-BCR expression and actively promoting Igκ rearrangement.  
Recent studies have found that the Ikaros-family transcription factor Aiolos 
downregulates λ5 expression through interaction with its promoter (Thompson et al. 
2007).  Importantly, expression of Aiolos in pre-B cells is dependent upon the presence 
of SLP65, suggesting that pre-BCR signaling downregulates pre-BCR surface expression 
through a negative-feedback loop.  SLP65 has also been implicated in activating Igκ 
gene rearrangement as pre-B cells from SLP65 mutant mice displayed reduced Igκ 
germline transcription and rearrangement (Hayashi et al. 2003).  Interestingly, SLP65 
mutant mice that also express a mutated form of the membrane co-receptor CD19 (Fig. 
1-2) experienced greater reductions in both measures, suggesting that multiple 
pathways downstream of the pre-BCR likely regulate IgL recombination.  SLP65 also 
appears to promote Igκ rearrangement through inhibition of Akt, thereby promoting 
Foxo activity (Herzog et al. 2008), as well as via regulation of interferon-regulatory 
factor 4 (IRF-4) (Thompson et al. 2007), a critical B cell regulatory factor (see below).   
Downstream of the pre-BCR, several additional factors contribute to the 
regulation of IgL recombination.  Two targets for the control of Igκ transcription and 
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rearrangement are enhancers elements located within the locus (Fig. 1-3).  The murine 
Igκ locus is comprised of roughly 120 Vκ gene segments located at the 5’ end of the 
locus and spanning a distance of approximately 30Mb (Roschenthaler et al. 1999).  20kb 
downstream of the Vκ gene segments are 5 Jκ gene segments, of which 4 are functional 
(Jκ3 is a pseudogene (Max et al. 1979)), followed by the κ-constant region (Cκ) which is 
located 2.5kb downstream of Jκ5 (Kirschbaum et al. 1998; Kirschbaum et al. 1999).  One 
of the Igκ enhancers, iEκ, is located in the intron between Jκ and Cκ (Picard and 
Schaffner 1984), while the second, 3’Eκ, is located 9kb downstream of Cκ (Meyer and 
Neuberger 1989).  Deletion of these enhancers revealed their critical role in driving Igκ 
rearrangement.  Deletion of either iEκ (Takeda et al. 1993; Xu et al. 1996) or 3’Eκ 
(Gorman et al. 1996) resulted in decreased Igκ rearrangement and fewer Igκ expressing 
B cells, while simultaneous deletion of both enhancers resulted in a complete block in 
Igκ rearrangement, indicating that the enhancers have synergistic effect (Inlay et al. 
2002). 
Although several transcription factor binding sites have been identified in the 
enhancers, to date E2A is the only transcription factor whose binding has been shown to 
be critical for Igκ rearrangement, as mutation of E2A binding sites in iEκ reduced Igκ 
rearrangement to a similar degree as iEκ deletion (Inlay et al. 2004).  In addition to E2A, 
the transcription factors IRF-4 and IRF-8 activate and promote Igκ rearrangement.  
These two transcription factors are highly homologous to one another and are 
expressed exclusively in lymphocytes (Tamura et al. 2008).  Both IRF-4 and 8, when 
complexed with the Ets-family members PU.1 or Spi-B, bind to an Ets-IRF composite 
element within the 3’Eκ, suggesting a role in regulating Igκ activity (Eisenbeis et al. 
1995).  Indeed, IRF-4/8 double mutant mice demonstrated a block in B cell development 
at the pre-B cell stage, with a loss of IgM+ cells and deficient Igκ germline transcription 
and rearrangement (Lu et al. 2003).  Interestingly, either IRF-4 or IRF-8 alone was 
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sufficient to rescue development and promote Igκ rearrangement in double mutant 
mice, indicating their functional redundancy (Ma et al. 2006).  Additionally, IRF-4, 
together with Spi-B, have been shown to be sufficient to promote germline transcription 
of the Igκ locus in Abelson murine leukemia virus-transformed pro-B cell lines (Muljo 
and Schlissel 2003). 
The mechanisms for IRF-4,8 mediated regulation of IgL rearrangement are still 
being characterized, however, Singh and colleagues recently reported that IRF-4 may 
influence Igκ recombination by two independent pathways (Johnson et al. 2008).  First, 
IRF-4 was observed to promote IgL recombination by positioning Igκ alleles away from 
centromeric heterochromatin, which presumably increases Rag accessibility (Johnson et 
al. 2008).  Additionally, IRF-4 was found to influence interleukin 7 (IL-7) signaling in 
pre-B cells.  The IL-7 receptor (IL-7R) is required for B cell development, as IL-7R 
deficient mice display arrested development at the pro-B cell stage (Peschon et al. 
1994).  Specifically, it is thought that IL-7 signaling promotes survival of pro-B cells and 
proliferation of early pre-B cells.  Importantly, after proliferation, late pre-B cells are 
less responsive to IL-7 which promotes IgL rearrangement by upregulation of Rag 
(Marshall et al. 1998; Johnson et al. 2008).  IRF-4 may be involved in this decreased 
responsiveness by facilitating migration of pre-B cells away from IL-7 expressing 
stromal cells in the bone marrow.  IRF-4 induced expression of the chemokine receptor 
CXCR4 in pre-B cells, which is significant since CXCL12, the ligand of CXCR4, is 
expressed by a small group of bone marrow stromal cells that are separated from those 
that express IL-7 (Tokoyoda et al. 2004), and suggests that IRF-4 mediated expression 
of CXCR4 results in the migration of pre-B cells away from IL-7.  Furthermore, 
decreased IL-7 signaling resulted in enhanced binding of E2A to the Eκi which, along 
with the finding that recruitment of E2A to 3’Eκ is dependent on IRF-4 (Lazorchak et al. 
2006), indicates that IRF-4 also enhances IgL rearrangement through indirect activation 
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of Igκ enhancers.  Together these findings reveal that IRF-4 orchestrates several discrete 
pathways in order to drive the development of pre-B cells and promote IgL 
rearrangement. 
 
Mechanisms of Immunological Tolerance 
The generation and expression of surface IgM in immature B cells represents 
another critical developmental checkpoint and is also the first point at which BCR 
specificity can be assessed.  As discussed earlier, BCR diversity is generated through the 
recombination of Ig gene segments at both the heavy and light chain loci.  Along with 
the random association of IgH and IgL chains, this combinatorial diversity provides the 
potential to produce over 1.9x106 unique receptors (Janeway et al. 2008).  Due to the 
random nature of the process, however, it is also possible to generate BCRs that 
recognize host or self-antigens.  Indeed, several studies suggest that a high proportion 
of newly generated BCRs are autoreactive.  Through random IgH and IgL pairing studies 
in Ig transgenic mice thought to mimic IgH/IgL pairing in vivo, Novobrantseva et al. 
found that 9 out of 18 BCRs tested showed signs of autoreactivity (Novobrantseva et al. 
2005).  Unfortunately, the authors did not confirm BCR autoreactivity directly, instead 
choosing to measure pre-B cell compartment expansion and endogenous IgL 
rearrangement, both of which are indicative of receptor editing, a process of continued 
IgL rearrangement associated with autoreactivity (see below). 
More conclusive evidence for immature B cell autoreactivity came from studies by 
the Nussenzweig lab.  In these experiments IgH and IgL chains were cloned from single 
immature and mature human B cells and tested for autoreactivity (Wardemann et al. 
2003).  The authors found that compared to mature cells, IgH chains from immature B 
cells possessed longer complementarity determining regions 3 (CDR3s) which is a 
feature associated with autoreactive BCRs (Ichiyoshi and Casali 1994; Crouzier et al. 
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1995; Klonowski et al. 1999).  Additionally, when the antibodies were tested for 
reactivity to cellular antigens, antibodies from immature cells were found to be highly 
autoreactive with nearly 76% displaying high levels of reactivity in a HEp2 ELISA.  
Furthermore, 55% of the immature B cell derived antibodies were also found to be 
polyreactive, as they demonstrated high degrees of reactivity to single- and double-
stranded DNA (ssDNA and dsDNA), insulin, and the bacterial antigen LPS.  Interestingly, 
the frequency of autoreactive B cells gradually declined as the B cells matured, as fewer 
antibodies from early emigrant peripheral (transitional) B cells were found to bind 
autoantigens and even fewer from fully mature cells.  This finding suggests that 
although autoreactive B cells may be plentiful in the immature pool, they are likely 
altered or removed so that the mature B cell population is mostly non-autoreactive.  
Consistent with this idea, a higher frequency of autoreactive B cells were found among 
murine transitional B cells than mature follicular B cells (Merrell et al. 2006). 
If allowed to fully mature and participate in immune responses, autoreactive B 
cells could mediate host cell damage and promote autoimmune disease.  Consequently, 
several self-tolerance mechanisms exist to restrict the development or activation of 
autoreactive B cells.  Studies using BCR transgenic mice have revealed three major 
tolerance mechanisms that act to influence the fate of autoreactive B cells, namely clonal 
deletion, anergy, and receptor editing.  Clonal deletion refers to the elimination of 
autoreactive cells, while anergy refers a non-responsive state that lymphocytes can 
adopt such that they no longer respond to their cognate antigens.  Receptor editing is 
the process whereby B cells with a functional BCR continue Ig rearrangement (primarily 
at the IgL locus) in order to alter BCR specificity.  The system that controls which 
tolerance mechanism is engaged in autoreactive B cells is not fully understood, however, 
BCR affinity for self-antigen appears to be important.  Goodnow and colleagues found 
that autoreactive B cells were anergized when presented with a soluble self-antigen, 
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however, when the same antigen was expressed as a membrane protein, the self-
reactive B cells underwent clonal deletion (Hartley et al. 1991).  Since membrane bound 
proteins are likely to interact with B cells in multivalent structures, it was proposed that 
increased BCR signaling caused deletion, while inefficient signaling by soluble molecules 
resulted in anergy.  Consistent with this model, Fulcher et al. found that transferred 
autoreactive B cells persisted longer in the spleens of mice expressing a soluble form of 
autoantigen compared to those expressing a membrane-bound form (Fulcher et al. 
1996). 
The studies by Nemazee and Bürki were the first to conclusively demonstrate 
clonal deletion as a mechanism of tolerance (Nemazee and Burki 1989).  In these 
experiments transgenic mice were generated that produced B cells expressing an IgM 
specific for H-2k MHC class I haplotype (3-83 idiotype (Id)).  These mice were then bred 
onto backgrounds with differing MHC class I haplotypes.  In mice expressing the MHC 
class I H-2d haplotype, 3-83Id+ B cells were frequent, comprising up to 50% of splenic B 
cells.  However, in H-2d/k mice, which also express the H-2k haplotype, no transgene 
expressing B cells were found.  Intriguingly, H-2d/k mice still possessed splenic IgM+ B 
cells, however, the total number was decreased by approximately 50%, suggesting that 
the 3-83Id+ cells were selectively removed from the repertoire.  These findings were 
confirmed in experiments by the Goodnow lab using a separate transgenic model 
(Hartley et al. 1993).  In double transgenic mice (anti-HEL/mHEL mice), which express 
hen egg lysozyme (HEL) ubiquitously on the cell surface and also generate anti-HEL B 
cells, the authors found that the autoreactive cells died in 1 to 3 days.  Interestingly, 
they observed that death of these cells was preceded by developmental arrest, which 
could be reversed with the removal of HEL.  Additionally, they were able to prolong the 
survival of anti-HEL B cells through the forced expression of the anti-apoptosis gene 
bcl-2, suggesting that deletion of the cells occurred via the apoptotic pathway.  In 
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subsequent studies, Kuramari et al. induced apoptosis in vivo through the introduction 
of self-antigen to anti-autoreactive B cells.  These B cells expressed BCRs specific for 
red blood cells (RBCs) and had escaped tolerance by migrating to the peritoneum.  
However, upon injection of RBCs into the peritoneum the autoreactive cells efficiently 
underwent apoptosis, as measured by DNA fragmentation (Murakami et al. 1992). 
Anergy is an alternative fate for B cells that recognize self-antigen.  The studies 
of anti-HEL transgenic mice by Goodnow and colleagues in 1988 were the first to 
describe this phenotype (Goodnow et al. 1988).  They observed that instead of being 
deleted, when anti-HEL-reactive B cells developed in the presence of secreted HEL they 
entered a state of unresponsiveness marked by loss of IgM secretion and decreased IgM 
(but normal IgD) surface expression.  In contrast, Erikson et al. observed in the anti-
DNA heavy chain transgenic model 3H9, that although autoreactive cells were anergized, 
as determined by low serum IgM levels, the surface IgM expression of these cells was 
unchanged.  This finding suggests that decreased IgM expression is not always 
indicative of anergic cells.  Additionally, Clarke and co-workers found that anergic B 
cells in an anti-Sm transgenic model displayed an immature B cell phenotype, 
expressing high levels of heat-stable antigen (HSA) and lacking expression of CD23 
(Santulli-Marotto et al. 1998).  Thus, these reports demonstrate that anergic B cells in 
autoreactive BCR transgenic models can adopt variable phenotypes.  To address this 
problem Merrell et al. sought to characterize anergic cells in the context of a wild-type B 
cell repertoire.  Using two different transgenic models of anergy, they defined anergic 
cells as having a T3-like phenotype (AA4.1+, CD23+, IgMlow) and also found that they 
expressed high levels of IgD and levels of HSA intermediate between T2 and mature 
follicular cells (Merrell et al. 2006).  Furthermore, these T3-like cells were not found in 
transgenic models known to lack anergic B cells.  Importantly, using this phenotype the 
authors were able to identify anergic B cells from wild-type mice.  This group of cells 
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did not proliferate or secrete IgM in response BCR stimulation and was found to be 
enriched for autoreactive cells.  The molecular mechanisms responsible for the anergic 
phenotype appear to be related to altered signaling, as the cells demonstrate impaired 
tyrosine phoshporylation after BCR aggregation (Cooke et al. 1994) and have altered 
intracellular Ca2+ concentrations, which are elevated basally and do not increase after 
BCR stimulation (Benschop et al. 2001). 
Increasing evidence indicates that receptor editing plays a major role in the 
regulation of self-tolerance.  This process involves the continued rearrangement of Ig 
genes, primarily at the IgL loci, in order to achieve an alteration in BCR specificity.  The 
structure of the Igκ locus is ideally suited for editing rearrangements due to the 
presence of multiple Jκ gene segments (Figure 1-4).  In B cells with existing VκJκ 
rearrangements, upstream un-rearranged Vκ gene segments are able to recombine with 
downstream unused Jκ gene segments, thereby “leap-frogging” the existing 
rearrangement and producing a new IgL variable region with a new specificity.  
Additionally, in situations where all Jκ gene segments have been exhausted, Vκ genes 
(or an RSS in the Jκ-Cκ intron) can rearrange to the recombining sequence (RS, also 
known as the κ deleting element (KDE) in humans) (Durdik et al. 1984; Siminovitch et al. 
1985).  Rearrangement to RS, which is located approximately 25kb downstream of Cκ, 
results in functional inactivation of the Igκ allele through disruption (either deletion or 
inversion) of Cκ.  Thus, RS recombination can promote rearrangement on the second Igκ 
allele or at the Igλ locus (Muller and Reth 1988).  Indeed, it appears that IgL 
rearrangement occurs in an ordered manner with Igκ rearrangement occurring first, 
followed by RS recombination, and then Igλ rearrangement.  Studies in mice with 2, 1, or 
no Igκ alleles revealed that delayed Igλ rearrangement occurs independently of Igκ 
rearrangement (Arakawa et al. 1996) and examination of rearrangement kinetics in pre-
B cell lines revealed a hierarchy among IgL rearrangements (van der Burg et al. 2002; 
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Klein et al. 2005).  These findings lead to the suggestion that RS recombination may 
serve to activate Igλ rearrangement directly through generation of a protein from the RS 
rearrangement, by activation of an Igλ enhancer, or by removing an Igλ suppressor 
(Persiani et al. 1987).  However, studies of RS-derived RNA transcripts revealed that they 
were insufficient to induce Igλ rearrangement (Daitch et al. 1992).  Furthermore, mice 
lacking the ability to rearrange RS were still capable of producing Igλ+ B cells (Chen et al. 
1993; Zou et al. 1993), suggesting that RS rearrangement is not a prerequisite for Igλ 
recombination.  Despite these findings, in mice bearing a targeted deletion of RS, 
Nemazee and co-workers found a decrease in the number of Igλ+ B cells indicating that 
although not required, RS recombination may promote development of Igλ-expressing B 
cells (Vela et al. 2008). 
The process of receptor editing was first described in two separate studies by the 
Nemazee and Weigert labs.  Using anti-H-2k,b transgenic mice (3-83Id), Tiegs et al. 
observed that when the membrane-bound autoantigens H-2k or H-2b were present, 3-
83Id+ B cells were removed from peripheral lymphoid organs, but could still be found in 
the bone marrow (Tiegs et al. 1993).  Further analysis of 3-83Id+ cells in the bone 
marrow revealed that they expressed increased levels of Rag-1 and Rag-2 mRNA 
compared to idiotype positive cells that had not encountered self-antigen.  Additionally, 
Rag levels were further increased if the cells encountered a higher affinity autoantigen.  
Possible V(D)J recombination implied by increased Rag expression was confirmed by 
qPCR of excision products, which are DNA segments removed from the chromosome 
during Ig gene rearrangement.  The benefit of these rearrangements was demonstrated 
by the visualization of 3-83Id+ bone marrow cells that expressed endogenous Igλ and 
the finding that virtually all Igλ+ peripheral B cells were also 3-83Id+.  Similarly, the 
Weigert lab used a double IgH/IgL transgenic model to study the fate of anti-dsDNA B 
cells (Gay et al. 1993; Radic et al. 1993).  They observed that among peripheral B cells 
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virtually all IgM+ cells expressed the transgenic IgH, however, none of these cells 
retained expression of the transgenic IgL, suggesting that they had generated new light 
chains.  Endogenous IgL rearrangement was confirmed by detection of Igκ gene 
rearrangement and mRNA transcripts in double-transgenic hybridomas.  Interestingly, 
the light chain usage among peripheral cells was restricted to a few Vκ genes, 
suggesting that these light chains in particular were able to abrogate DNA binding and 
prevent cell death by clonal deletion.  Consistent with this model, Radic et al. observed 
that hybridomas generated from splenocytes of single 3H9 IgH transgenic mice no 
longer bound dsDNA and expressed a limited set of light chains, indicating that only 
light chains able generate non-autoreactive BCRs with 3H9 survived and completed 
development (Radic et al. 1993).  Additionally, these hybridomas demonstrated skewed 
usage of distal Jκ genes (Jκ5) which is indicative of continued Ig rearrangement and 
suggests that these cells where tolerized via receptor editing.  Similar results were also 
observed in 3H9 transgenic mice that carried only one functional Igκ allele (Prak et al. 
1994). 
The overall contribution of receptor editing to B cell tolerance has been difficult 
to determine, however, recent data may provide more accurate estimates of editing 
frequencies.  Calculating receptor editing levels in the transgenic models described 
above is unreliable due to the nature of the Ig transgenes used.  Unlike normally 
expressed Ig chains which can be directly silenced through receptor editing 
rearrangements, the conventional transgenes employed in these models are not located 
in the endogenous loci and consequently cannot be removed through V(D)J 
recombination.  Therefore, frequencies from these models may underestimate receptor 
editing as more B cells will undergo clonal deletion due to the inability to silence 
transgene expression.  To address this issue Eline Luning Prak and Martin Weigert 
generated site-directed transgenic (sd-tg) mice in which the endogenous Jκ locus was 
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replaced with a functional Vκ4Jκ4 or Vκ8Jκ5 rearrangement (Prak and Weigert 1995).  
Because of the location of these transgenes and the retention of an endogenous 
downstream Jκ5 gene segment in the Vκ4 mice, B cells from these mice could silence the 
IgL transgenes via physiologic receptor editing rearrangements.  Indeed, hybridomas 
generated from these mice revealed that additional IgL rearrangements took place not 
only on the endogenous allele, but on the transgenic allele as well.  Additionally, these 
mice were bred with mice carrying a sd-tg for the 3H9 IgH (Chen et al. 1995), to create 
double sd-tg mice expressing anti-DNA antibodies (Chen et al. 1997).  Analysis of 
hybridomas revealed that the mice did not harbor anti-DNA B cells and genetic studies 
demonstrated that this loss of autoreactivity was largely achieved by IgL rearrangement.  
Strikingly, 85% of hybridomas from 3H9/Vκ4 mice had undergone IgL rearrangement on 
the targeted allele, while only 11% rearranged the endogenous allele without first 
inactivation the Vκ4 transgene.  Similar results were observed by the Rajewsky and 
Behrens labs in a separate sd-tg systems (anti-MHC class I and anti-HEL, respectively), 
where they found increased receptor editing levels that correlated with B cells 
expressing autoreactive BCRs (Pelanda et al. 1997; Hippen et al. 2005).  Furthermore, 
using a system in which Igκ alleles can be distinguished by differences in Cκ, 
Nussenzweig and colleagues observed that approximately 25% of BCRs are generated via 
editing rearrangements (Casellas et al. 2001).  Together these findings highlight the 
efficiency of receptor editing and suggest a role for receptor editing in tolerance 
induction in normal mice. 
To date the most definite evidence demonstrating the significance of receptor 
editing in maintaining tolerance has come from studies of autoreactive sd-tg B cells in 
the context of a polyclonal repertoire (Halverson et al. 2004).  In these studies Pelanda 
and co-workers generated chimeric mice that possess a subset of B cells expressing the 
3-83Id (anti-H-2k,b) IgH and Igκ chains.  The ratio of 3-83Id and wild-type cells mixed 
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varied in different chimeric mouse strains and provided a means of tracking the survival 
of the autoreactive B cells.  Remarkably, transgene bearing B cells were not deleted and 
instead had replaced the transgenic Igκ chain with an endogenous Igκ, indicating that 
editing was highly efficient at rescuing these autoreactive cells from deletion.  
Importantly, when receptor editing was limited by removing free Jκ gene segments in 
the Igκ locus, up to 50% of the transgenic autoreactive cells underwent clonal deletion 
suggesting that receptor editing is the dominant form of central tolerance. 
 
Clearly receptor editing is an important mechanism of B cell tolerance, however, 
our understanding of the role of editing in a wild-type repertoire has been hindered by 
the dependence on transgenic mouse models.  Although these models can help us 
understand the causes and consequences of receptor editing, expression of transgenic 
Ig chains can complicate the interpretation of results due to alterations in B cell 
development.  Moreover, they cannot tell us about the significance of editing in a wild-
type polyclonal repertoire.  Common markers of receptor editing, such as distal Jκ and 
increased Igλ usage that could be applied to wild-type mice, are confounded by clonal 
selection which can influence these measures.  To address this problem, I developed a 
novel assay for measuring receptor editing rearrangements which does not rely upon 
surface BCR components that are subject to selection.  Additionally, as editing may be 
important in preventing autoimmune disease, I examined mouse models of 
autoimmunity to determine if defects in receptor editing contribute to disease.  These 
experiments were then translated to human patients with autoimmune disease.  Finally, 
to investigate the forces that stimulate receptor editing, precursor rearrangements were 
analyzed in order to determine if editing is dependent upon self-antigen signaling.  If 
this is the case, then functional precursors should be enriched for autoreactive IgL 
chains. 
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 Figure 1-1 
 
 
Figure 1-1:  B cell development is an ordered process involving progressive stages 
of maturation defined by changes in protein expression and gene transcription 
(adapted from (Hardy et al. 2007)).  Surface protein expression of different stages in B 
cell development are depicted in the first 7 rows.  Gene transcription as determined by 
mRNA quantification or reporter constructs are depicted in the following 5 rows.  The 
final two rows depict the status of ongoing immunoglobulin gene rearrangement during 
various stages of development.  Darker lines depict increased expression.  Letters 
designate bone marrow fractions as described in (Hardy et al. 1991).  Abbreviations: 
MPP, multipotent progenitor; CLP, common lymphoid progenitor; Fo, follicular B cell; 





Figure 1-2:  Pre-B cell receptor signaling regulates pre-B cell proliferation and 
differentiation (adapted from (Herzog et al. 2009)).  The pre-B cell receptor (pre-BCR) 
is expressed at the pre-B cell stage and is comprised of two IgH chains that each pair 
with a surrogate light chain (SLC).  The SLC itself is a complex of two proteins, λ5 and 
VpreB.  The paired IgH and SLC represent the extracellular components of the pre-BCR 
that associate with Igα and Igβ, which serve to propagate signals within the cell.  
Ligation of the pre-BCR leads to recruitment of tyrosine kinases, such as Syk , that 
initiate the signaling cascade.  Activation of phosphoinositide 3 kinase (PI3K) leads to 
activation of protein dependent kinase 1 (PDK1) which in turn activaes Akt, a potent 
regulator of cellular proliferation.  Additionally tyrosine kinases act upon SH2-domain 
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containing leukocyte protein of 65kDa (SLP65) which once phosphorylated can interact 
with additional signaling molecules, including Bruton’s tyrosine kinase (Btk) and 
phospholipase Cγ2 (PLCγ2).  Recently SLP65 has been shown to block Akt inhibition of 
the transcription factor Foxo1 (Herzog et al. 2008), while PLCγ2 has been shown to 
upregulate expression of interferon regulatory factor-4 (IRF-4) (Bai et al. 2007), 
suggesting that this arm of pre-BCR signaling is important for pre-B cell differentiation 





Figure 1-3:  Schematic of the germline murine Igκ locus (adapted from (Schlissel 
2004)).  The germline Igκ locus is displayed with exons depicted as boxes and introns as 
dark lines.  Recombination signal sequences (RSSs) are depicted as triangles with open 
triangles representing 12bp RSS spacers and filled triangles are 23bp spacers.  Ovals 
depict the two Igκ transcriptional enhancer elements.  The recombining sequence (RS) is 
located approximately 25kb downstream of Cκ and can recombine with upstream Vκ 





Figure 1-4:  Receptor editing at the Igκ locus.  (a) Schematic of the murine Igκ light 
chain locus illustrating a primary Vκ-Jκ rearrangement followed by a “leap-frogging” 
editing rearrangement involving an upstream 5’ Vκ gene segment and a downstream 
unrearranged Jκ gene segment.  In situations where free Jκ gene segments have been 
exhausted, editing can continue via RS rearrangement.  Two pathways of RS 
rearrangement are available.  The first (1) involves recombination of an upstream 
unrearranged Vκ gene segment to RS, while the second (2) utilizes a non-canonical 
recombination signal sequence (iRS) in the Jκ-Cκ intron to rearrange to RS.  Both result 
in the deletion of Cκ and functional inactivation of the Igκ locus.  Exons are given as 
boxes, recombination signals are indicated by triangles and dashed lines with arrows 
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 INTRODUCTION 
B cells undergo a random process of V(D)J recombination in order to generate 
the many distinct receptors needed to recognize a vast array of antigens.  An inevitable 
consequence of this random process is the production of autoreactive B cells 
(Wardemann et al. 2003).  An important mechanism for tolerizing autoreactive B cells is 
receptor editing (Halverson et al. 2004).  Receptor editing results in the alteration of B 
cell receptor specificity and is achieved by ongoing immunoglobulin (Ig) gene 
rearrangement, most commonly at the light chain loci (Gay et al. 1993; Radic et al. 
1993; Tiegs et al. 1993).  Light chain rearrangement proceeds in an ordered fashion as B 
cells develop in the bone marrow, with κ genes recombining first, followed by 
rearrangement of the Recombining Sequence and λ (Lewis et al. 1982; Muller and Reth 
1988).  The Recombining Sequence (known as the Kappa Deleting Element (KDE) in 
humans, hereafter RS) is a non-coding gene segment located 25kb downstream of Cκ in 
the κ locus that is rearranged during continued Ig light chain gene rearrangement 
(Durdik et al. 1984; Siminovitch et al. 1985). 
Due to the unique structure of the κ locus, primary Vκ-Jκ rearrangements that 
are non-functional or autoreactive can be replaced via “leap-frogging” recombination of 
un-rearranged upstream Vκ- and downstream Jκ-gene segments to form new κ light 
chains (Fig. 2-1a).  Additional rearrangement attempts can be made through 
recombination at the second κ allele or at λ.  Recombination of RS to upstream Vκ-gene 
segments or a recombination signal sequence (RSS) within the Jκ-Cκ intron results in the 
deletion or inversion of Cκ and functional inactivation the κ locus (Fig. 2-1a).  Because 
RS rearrangements do not encode any functional proteins (Daitch et al. 1992), 
monitoring RS rearrangement provides a specificity-independent means of measuring 
repeated rearrangement attempts at κ (receptor editing). 
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The original studies characterizing RS recombination postulated that it served to 
promote λ rearrangement by either repressing κ rearrangement or activating the λ locus 
(Persiani et al. 1987; Muller and Reth 1988).  However, λ-expressing B cells can form 
without undergoing RS rearrangement, indicating that RS is not required for the 
production of λ (Zou et al. 1993).  When RS rearrangement is prevented in RS knock-out 
mice, receptor editing is inefficient and autoreactive B cells are found among peripheral 
cells (Vela et al. 2008), highlighting the potential role of RS in establishing central 
tolerance and reducing light chain allelic and isotypic inclusion. 
Current clinical assays that evaluate B lymphocyte tolerance focus on serum 
autoantibodies, which are products of mature B cells.  Because secreted autoantibodies 
are an end-product rather than an intermediate, they do not distinguish between 
autoimmunity that arose during primary B cell maturation or later due to events such as 
somatic mutation.  The distinction is important because a defect in primary B cell 
tolerance may predict disease development.  Furthermore, diseases occurring as a result 
of a primary B cell tolerance defect may be associated with resistance to B cell targeted 
therapy because the primary repertoire is predicted to rapidly repopulate with 
autoreactive cells if B cell reconstitution is allowed to proceed.  Before testing those 
ideas, an assay for central B cell tolerance is needed. 
This manuscript describes the development and initial characterization of RS 
rearrangement frequency as an assay for central B cell tolerance in systemic lupus 
erythematosus (SLE) and type 1 diabetes (T1D).  In both of these diseases B cells play a 
critical pathogenic role.  Autoantibodies are a prominent feature, whether they be 
directed against nuclear antigens (in SLE) (Tan 1982) or pancreatic β-cell antigens such 
as GAD65 or insulin (in T1D) (Leslie and Delli Castelli 2004).  Furthermore, B cell 
deficiency or depletion in mouse models ameliorates or prevents disease (Shlomchik et 
al. 1994; Serreze et al. 1996; Noorchashm et al. 1997; Ahuja et al. 2007; Hu et al. 
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2007).  The results with B cell depletion therapy in humans are equivocal for SLE 
(EXPLORER study - ClinicalTrials.gov identifier: NCT00137969) and not yet fully 
explored in T1D.  Here we describe the status of central tolerance in individuals with SLE 
or T1D using RS rearrangement frequency as a marker. 
 
RESULTS 
A novel assay for estimating levels of receptor editing 
We focused on RS rearrangement as an assay for receptor editing because RS 
rearrangement is known to accompany extensive light chain rearrangement during 
primary B cell maturation (Persiani et al. 1987; Klein et al. 2005) and the major RS 
rearrangement products are defined and share a common DNA sequence (Siminovitch et 
al. 1987).  Most importantly, RS rearrangements do not encode a functional protein 
(Daitch et al. 1992), and therefore are independent of antibody specificity, making their 
measurement potentially applicable to any disease in which B cells play a pathogenic 
role.  By combining a quantitative PCR assay for RS rearrangement frequency with cell 
sorting, receptor editing can be analyzed in different B cell subsets (Fig. 2-2). 
We analyzed the most abundant class of RS rearrangements, which are Vκ to RS 
in mice and iRS to RS in humans (Retter and Nemazee 1998; Brauninger et al. 2001). For 
the human studies, iRS to RS rearrangements were quantified relative to an absolute 
standard consisting of a cloned iRS-RS rearrangement that was serially diluted in 
fibroblast DNA.  Log-linear amplification was observed over the range of 0.7-200% RS 
rearrangements per cell genome (Fig. 2-3).  200% corresponds to having two RS 
rearrangements, one on each κ allele.  Typical RS frequency measurements fall within 
this log-linear range.  For the mouse studies a degenerate Vκ primer was used for RS 
rearrangement measurements (Schlissel and Baltimore 1989).  Murine Vκ-RS 
rearrangements were quantified as fold difference relative to IgM+, κ+ spleen DNA from 
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B6 mice (the spleen contains a mixture of different Vκs).  Fold differences were used 
rather than absolute frequencies in order to avoid confounds caused by differing 
amplification efficiencies for different Vκ genes.   
The correlation between RS rearrangement and extensive light chain 
rearrangement has been established in earlier work from several groups (Durdik et al. 
1984; Moore et al. 1985; Siminovitch et al. 1985; Dunda and Corcos 1997; Retter and 
Nemazee 1998; Brauninger et al. 2001).  Consistent with these earlier reports, RS 
rearrangement is increased 8-fold amongst λ+ murine IgM+ B cells compared to κ+ cells 
(Fig. 2-1b).  Amongst CD19+ human B cells, 16% of κ+ B cells carried an RS 
rearrangement and the frequency of RS rearrangements amongst λ+ B cells was greater 
than 100%, indicating that some λ+ B cells have rearranged to RS on both κ alleles. 
Because RS levels are higher in λ+ than in κ+ B cells, the overall RS rearrangement 
frequency correlates inversely with the κ/λ ratio. To reduce the variability in RS 
frequency measurements introduced by the κ/λ ratio, RS analysis was performed 
separately in κ+ or λ+ cells.  However, it is important to note that RS rearrangement 
levels in a given κ+ or λ+ B cell population vary independently from the overall κ/λ ratio 
(Fig. 2-4 and Fig. 2-9a).  Thus, measuring the RS frequency is not simply a 
cumbersome method for assessing the κ/λ ratio.  Also of note, RS rearrangement 
frequencies are correlated in κ and λ-expressing B cells within single individuals.  (This 
intra-individual correlation and the concept of an RS set point will be addressed in the 
analysis of human subjects below). 
 
RS rearrangement levels vary between developmental and functional B cell subsets 
in mice 
If RS rearrangement is a marker of ongoing antibody light chain rearrangement, 
it should occur at the time of late κ or λ rearrangement.  Consistent with this prediction, 
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the highest level of RS rearrangement was found among bone marrow fraction D cells 
(small pre-B II cells (Hardy et al. 1991), hereafter Fr. D), which are cytoplasmic Igµ+, but 
no longer express surrogate light chain.  Fraction D cells express the Rag1 and Rag2 
proteins for light chain gene rearrangement (Fig. 2-5a) (Hardy et al. 1991).  Further 
subsetting within Fr. D based upon BP-1 expression, revealed that the majority of RS 
rearrangements most likely occurred towards the end of this period (Fig. 2-5b). 
In the subsequent developmental subset, Fr. E (newly formed IgM+ immature B 
cells), Vκ-RS rearrangement levels were reduced by 3-fold and closer to those of 
mature, circulating B cells (Fr. F).  The difference in Vκ-RS rearrangement levels between 
Fr. D cells and κ+ Fr. E cells could be due to the inclusion of pre-B cells undergoing or 
completing λ rearrangement within Fr. D.  However, RS levels in total IgM+ Fr. E cells 
were similar to κ+ Fr. E cells, suggesting that exclusion of λ+ cells from Fr. E cannot fully 
account for the decrease.  Death of RS+ cells or their rapid exit from the bone marrow to 
a peripheral pool may contribute to the decrease in RS rearrangement levels in Fr. E 
relative to Fr. D. 
 
Mouse strains prone to autoimmunity display lower levels of RS rearrangement 
The preceding experiments established the developmental timing of RS 
rearrangement and documented a positive correlation between RS rearrangement 
frequency and an autoreactive antibody heavy chain in inbred mice.  To determine if RS 
rearrangement is altered in the context of autoimmunity, we measured RS 
rearrangement frequency in two different mouse models of autoimmune disease, 
MRL/lpr mice as a model of SLE and non-obese diabetic mice (NOD) mice as a model of 
T1D.  We observed decreases in RS rearrangement levels among Fr. D cells of both 
MRL/lpr (2.5-fold reduction, p<0.05) and NOD mice (3.7-fold reduction, p<0.01), when 
compared to C57Bl/6 mice (Fig. 2-6a).  Interestingly, fewer RS rearrangements were 
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also observed among Fr. E cells in both MRL/lpr and NOD mice relative to C57Bl/6 mice.  
This decrease was evident in the mature recirculating B cells of the bone marrow (Fr. F) 
as well, implying that unedited or minimally edited cells persisted through development.  
Measurement of RS levels in splenic B cell subsets further substantiated this finding (Fig. 
2-6b). 
To determine if the lower levels of Vκ-RS rearrangements detected in MRL/lpr 
and NOD mice are attributable to strain effects, rather than as a consequence of an 
autoimmune state, RS levels were measured in MRL/MpJ mice, which share the same 
genetic background as MRL/lpr mice but lack the Fas mutation that is responsible for 
their lymphocytosis and accelerated systemic autoimmunity.  Similarly, NOD mice were 
compared to NOR mice, which share the same diabetogenic MHC haplotype (H2g7) with 
NOD mice but are insulitis-resistant and do not develop T1D (Prochazka et al. 1992) 
(Fig. 2-7).  These "control" strains share the propensity to develop autoimmunity with 
MRL/lpr and NOD mice, but do so at a much slower pace.  The control mice were 
analyzed at 3 months of age, a time at which autoimmune pathology is not yet apparent.  
Although RS rearrangement levels were slightly increased among some bone marrow B 
cell subsets in the control mouse strains, levels in mature B cells were comparable in 
MRL/MpJ and NOR mice to their more autoimmune counterparts.  The low frequency of 
RS rearrangement in MRL/MpJ and NOR mice suggests that a reduced level of receptor 
editing predisposes towards the development of autoimmunity rather than arising as a 
consequence of autoimmune disease. 
 
RS rearrangement levels are lower in human SLE and T1D 
To further investigate the level of receptor editing in the context of defective 
tolerance, we compared RS rearrangement levels in peripheral B cells from human 
subjects with established disease (SLE or T1D) to healthy control subjects (see Methods).  
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For this analysis, we evaluated 26 control subjects, 24 patients with SLE and 25 patients 
with T1D.  Demographic features of the subject groups were compared and no 
significant differences were observed between control and SLE groups with respect to 
age, gender, and race; however the T1D group contained a larger proportion of men and 
Caucasians than the control and SLE groups (Table 2-1).  Nonetheless, RS frequencies 
were not correlated with subject age, gender, or race (Fig. 2-8). 
Amongst CD19+ κ+ B cells, RS rearrangement frequencies from SLE patients were 
lower on average compared to levels from healthy controls (Fig. 2-9a, p<0.01).  The RS 
rearrangement frequency in κ+ B cells from T1D was not significantly decreased 
compared to control subjects.  In CD19+ λ+ B cells RS levels were lower in both SLE and 
T1D patients compared to control subjects (Fig. 2-9b, p<0.01).  These results resemble 
those from the autoimmune mouse models and suggest that lower levels of RS 
rearrangement may be correlated with disease susceptibility. 
We chose the bottom 10th percentile of the normal population as an arbitrary 
cut-off for the RS rearrangement frequency distribution in κ+ B cells (κRS).  Using this 
cut-off, the fraction of subjects with a low κRS value is 2/26 for the healthy control 
subjects, 13/24 for SLE and 8/25 for T1D.  Using a similar λRS cut-off, 3/26 controls, 
9/23 SLE patients and 11/25 T1D patients had low RS levels.  Additionally, RS levels 
were low in both κ+ and λ+ B cells in 7/23 SLE and 7/25 T1D patients, indicating that 
subjects with low κRS levels tended to also have low λRS levels.  Indeed, Spearman 
correlations between the κRS and λRS measurements were significant in both healthy 
subjects and patients with autoimmune disease (r=0.54, p<0.01 and r=0.52, p<0.01, 
respectively; Fig. 2-9c).  Additionally, linear regression analysis revealed a lower degree 
of RS rearrangement in λ+ cells relative to levels in κ+ in patients with autoimmune 
disease compared to healthy controls.  Together these findings suggest that some SLE 




The development of assays to monitor B cell tolerance and selection stringency 
can inform the choice of B cell targeted therapy for autoimmune disease.  This 
contention is based upon the idea that individual patients with SLE and T1D have 
different tolerance defects (Florez et al. 2003; Harley et al. 2008).  Previous assays that 
monitor B cell tolerance are problematic because they tend to measure relatively late 
events such as autoantibody production, rather than the pathways that B cells take on 
their way to becoming autoimmune.  The RS rearrangement assay presented here takes 
two days to perform and provides insights into central (early) B cell tolerance.  
Furthermore, it can be combined with immunophenotyping to analyze editing levels in 
different peripheral B cell subsets.  As such, it may be possible in the future to use this 
assay to monitor and stage defects in B cell tolerance. 
The RS rearrangement assay gives an estimate of the overall level of light chain 
rearrangement in a defined population of B cells.  The correlation between RS level and 
the light chain rearrangement level is based on earlier studies documenting that 10 to 
15% of murine κ+ splenic B cells had undergone RS recombination, while virtually all λ+ 
splenic B cells harbored an RS rearrangement (Moore et al. 1985; Dunda and Corcos 
1997; Retter and Nemazee 1998).  Similarly, studies of single human B cells and acute 
lymphoblastoid leukemia cell lines demonstrated that cells expressing λ harbored more 
RS rearrangements than ones that expressed κ (Brauninger et al. 2001; van der Burg et 
al. 2002).  Furthermore, λ B cells took approximately 24 hours longer to label with BrdU 
than B cells with κ rearrangements (Arakawa et al. 1996).  Finally, studies in B cell 
leukemia cell lines subjected to Bcr-Abl tyrosine kinase blockade exhibited temporally 
ordered light chain rearrangements: κ followed by RS followed by λ (Klein et al. 2005).  
The current study is consistent with all of these previous studies: RS rearrangement 
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frequencies were higher in λ+ B cells than in κ+ B cells and were most frequent in late 
pre-B cells (Fr.D).  Every other B cell subset, including Fr. E (which is where surface 
antibody is first detected) and more mature splenic B cells, exhibited lower RS levels.  As 
RS rearrangements are non-revertible, these findings suggest that receptor editing fails 
to salvage some of the most highly edited B cells from clonal deletion.   
The current study demonstrates decreases in RS rearrangement frequency in 
mouse models of SLE and T1D.  Both MRL/lpr and NOD mice exhibited lower RS levels 
compared to wild-type C57Bl/6 mice.  The finding of lower editing levels in MRL/lpr 
mice is consistent with recent work from the Feeney lab demonstrating decreased 
receptor editing in response to a ubiquitous membrane bound self antigen in transgenic 
MRL/lpr mice (Lamoureux et al. 2007).  The finding of decreased RS rearrangement in 
NOD mice is at odds with a previous report in which editing was measured using a 
membrane bound facultative self-antigen (HEL) (Silveira et al. 2004).  The RS assay, 
however, does not focus on one kind of self-antigen. 
Although both MRL/lpr (Watanabe-Fukunaga et al. 1992) and NOD (Kishimoto 
and Sprent 2001) strains harbor previously characterized defects in apoptosis, lower RS 
levels were not linked these defects per se, as B cells from MRL/MpJ and NOR mice (both 
with intact apoptosis) also exhibited lower RS levels.  In the case of MRL/lpr mice, the 
additional defect conferred by the lpr mutation (Watanabe-Fukunaga et al. 1992) may 
lead to less stringent selection of minimally edited immature B cells.  Similarly, the 
finding of low RS rearrangement levels in both the NOD and NOR strains suggests that a 
second tolerance defect present only in NOD mice is required for development of 
diabetes.  However, the genetic backgrounds of these control strains predispose them to 
develop autoimmunity.  Despite having an intact Fas gene, MRL/MpJ mice spontaneously 
develop autoimmunity including pancreatitis (Kanno et al. 1992) and glomerulonephritis 
(Hewicker et al. 1990), but the disease is milder and occurs later in life.  NOR/LtJ mice 
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share the diabetogenic H2g7 haplotype with NOD mice and have altered macrophage and 
peripheral T cell compartments (Prochazka et al. 1992).  All of the mice used for these 
experiments were 3 months of age, which is at a time that precedes disease 
development in NOR and MRL/MpJ mice.  Together these findings suggest that 
decreased RS rearrangement levels in these mice reflect an altered propensity to develop 
autoimmunity. 
In humans, lower RS rearrangement levels were also detected in both SLE and 
T1D patients compared to healthy control subjects.  The decrease was most apparent in 
λ+ B cells, but the level of RS rearrangement was correlated in κ+ and λ+ B cells in 
individual patients.  The levels were not proportional to the κ/λ ratio or to the fraction of 
B cells in the blood.  These findings have theoretical and practical implications.  The 
theoretical implication is that individuals may have different RS rearrangement "set 
points."  The set points tend to be lower in T1D and SLE than in healthy subjects, but 
overlap to some degree.  It will be important to directly measure RS levels in different 
peripheral B cell subsets and determine if differences can be correlated with B cell 
selection checkpoints or if, in a fashion similar to the mouse models, different subsets 
will show correlated RS levels.  Up until now, selection checkpoints have been monitored 
by single cell antibody cloning and expression studies (Wardemann et al. 2003; Yurasov 
et al. 2005; Tsuiji et al. 2006).  If RS rearrangement can be used instead, it may be 
possible to more easily define B cell tolerance checkpoints in individual patients with 
autoimmune disease.  The practical implication of having correlated RS rearrangement 
frequencies in κ+ and λ+ B cells is that it may be possible to measure RS rearrangement 
frequency in whole blood rather than in sorted B cell subsets and then to correct the 
measurement for the B cell fraction and κ/λ ratio. 
Given the concordance of RS rearrangement levels in T1D and SLE, we considered 
the possibility that upstream genetic defects could decrease receptor editing in both 
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disorders.  One candidate is PTPN22 (protein tyrosine phosphatase non-receptor 22, 
also known as Lyp).  PTPN22 is a lymphoid specific phosphatase that suppresses T cell 
activation (Cohen et al. 1999).  A variant of PTPN22 (R620W) is common in both SLE and 
T1D (Bottini et al. 2004; Lee et al. 2007) and appears to have a more active phosphatase 
in the setting of T1D (Vang et al. 2005).  Although the effects of PTPN22 R620W are not 
yet well defined in B cells (Rieck et al. 2007), one is tempted to speculate that there 
could be an increased BCR signaling threshold due to PTPN22 R620W that would result 
in decreased receptor editing.  Other potential candidates include RAG or molecules that 
influence the intracellular localization or expression of RAG such as the nuclear importin 
KPNA1 (Glinsky 2008), interferon regulatory factor 4 (Johnson et al. 2008), or the 
transcription factor Foxo1 (Amin and Schlissel 2008; Herzog et al. 2008).  Because RS 
rearrangement frequency corresponds to a phenotype rather than a heritable genetic 
alteration, there could be several different defects, each of which could contribute 
independently to a low RS frequency. 
It is not yet clear what the biological consequences are of a low RS 
rearrangement frequency or if the lowest levels of RS rearrangement are inherently the 
most dangerous.  Perhaps individuals with low RS levels (including a small subset of 
currently healthy subjects) are at increased risk of developing autoimmunity.  In this 
regard, the prospective analysis of first-degree relatives of patients with autoimmunity 
might be especially informative.  It will also be important to find out how generalizable 
the RS rearrangement frequency is to other autoimmune diseases as a potential marker 
for defective central tolerance. 
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Figure 2-1:  RS rearrangement is a marker of extensive κ  light chain 
rearrangement.  (a) Schematic of the murine κ light chain locus illustrating successive 
Vκ-Jκ rearrangements followed by RS rearrangement.  Two pathways of RS 
rearrangement are available.  The first (1) involves recombination of an upstream 
unrearranged Vκ gene segment to RS, while the second (2) utilizes a non-canonical 
recombination signal sequence (iRS) in the Jκ-Cκ intron to rearrange to RS.  Both result 
in the deletion of Cκ and functional inactivation of the Igκ locus.  Exons are given as 
boxes, recombination signals are indicated by triangles and dashed lines with arrows 
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illustrate the rearrangements.  (b) RS rearrangement levels as measured in Igκ+ (gray 
bars) and Igκ- (presumed to be l+, black bars) from splenic B220+ IgM+ B cells of adult 
(3-4 month old) C57Bl/6 mice (n=5) and CD19+ 9G4- peripheral B cells from healthy 
control subjects (n=26).  All PCR reactions were performed in duplicate.  Murine data are 
presented as fold difference relative to the average RS level in C57Bl/6 splenic B220+ 
IgM+ Igκ+ B cells (+s.e.m.).  Human data are depicted as rearrangement frequency per 
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Figure 2-2:  Flow Cytometric Analysis of Murine and Human Lymphocytes.  
Cytometric analysis of bone marrow and splenic B cells from (a) C57Bl/6, (b) MRL/lpr, (c) 
NOD mice, and (d) healthy human subjects.  Plots represent 50,000 events followed by 
DAPI+ and doublet exclusion.  Murine bone marrow subsets include Fr. A-C’ (B220+, 
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CD43+), Fr. D (B220+, CD43-, AA4.1+, IgM-), Fr. E (B220+, CD43-, AA4.1+, IgM+), and Fr. F 
(B220+, CD43-, AA4.1-, IgM+).  Murine splenic populations were identified as follows: 
follicular B cells (B220+, AA4.1-, IgMint, CD23+), and marginal zone B cells (B220+, AA4.1-
, IgMbri, CD23-).  Due to poor reactivity of AA4.1 in NOD and NOR mice (Langmuir et al. 
1993; Quinn et al. 2006), bone marrow populations in these mice were defined as 
follows: Fr. D (B220+, CD43-, IgD-, IgM-), Fr. E (B220+, CD43-, IgD-, IgM+), and Fr. F 
(B220+, CD43-, IgD+, IgM+).  Human peripheral B cells were isolated on the basis of 
CD19, κ, and λ expression.  To maximize efficient use of patient samples for additional 
experiments not described here, CD19+ B cells marked by the anti-idiotypic monoclonal 
antibody 9G4, which recognizes VH4-34 heavy chain rearrangements (Isenberg et al. 
1993), were excluded from human CD19+ B cell populations described herein.  9G4Id+ 







Figure 2-3:  Real-time PCR to monitor iRS-KDE rearrangements in B cell 
populations. iRS-KDE rearrangements were amplified with 5’-ATT GAT GCT GCC GTA 
GCC-3’ and 5’-AGG CTT CCT AGG GAG GTC AG-3’ primers and detected with 5’-TCT 
GCA GCT GCA TTT TTG CCA-3’ FAM-labeled hydrolysis probe.  For each sample, the 
intronic region of the reference control gene β-actin was amplified in a separate well 
with forward primer 5’-CCC AGC ACA ATG AAG ATC AA-3’ and reverse primer 5’-AGT 
ACT TGC GCT CAG GAG GA-3’ and detected with a Cy5-labeled hydrolysis probe 5’-
TGC CTG AGC TGA CCT GGG CA-3’.  A cloned iRS-KDE rearrangement was serially 





Figure 2-4:  RS rearrangement levels amongst κ+ B cells are independent of Igκ/Igλ  
ratios.  (a) Vκ-RS rearrangement levels in splenic Igκ+ follicular B cells from individual 
C57Bl/6 (black circles, n=5, r=0.8, p=0.1), MRL/lpr (white squares, n=4, r=-0.6, 
p=0.4), and NOD (gray triangles, n=5, r=-0.7, p=0.2) mice compared to frequency of 
Igκ+ splenic follicular B cells.  RS rearrangement levels are calculated as fold difference 
relative to the average RS level in C57Bl/6 splenic B220+ IgM+ Igκ+ B cells.  (b) iRS 
rearrangement levels in CD19+ 9G4- Igλ+ (black diamonds, right y-axis) compared to 
CD19+ 9G4- Igκ/Igλ ratios (gray bars, left y-axis).  iRS rearrangement levels are depicted 
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from healthy control subjects (top panel, n=26), SLE patients (middle panel, n=23), and 





Figure 2-5:  RS rearrangement levels are highest in late pre-B cells.  (a) Vκ-RS 
rearrangement levels quantified in bone marrow (BM) subsets from C57Bl/6 mice (n=5).  
(b) Vκ-RS rearrangement levels assayed in less mature (BP-1+, gray bar) and more 
mature (BP-1-, black bar) Fr. D B cells of C57Bl/6 mice (n=3).  All PCR reactions were 
performed in duplicate.  Data are depicted as fold difference (+s.e.m., ** = p≤0.01) 
relative to the average RS level in C57Bl/6 splenic B220+ IgM+ κ+ B cells (dashed line).  
Bone marrow B cell fractions were obtained by flow cytometry, as shown in Fig. 2-2. 
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 Figure 2-6 
 
 
Figure 2-6:  Autoimmune prone mouse strains display reduced levels of RS 
rearrangement.  (a) Vκ-RS rearrangement levels in bone marrow subsets of MRL/lpr 
mice (white bars, n=4) and NOD mice (gray bars, n=5).  Data from C57Bl/6 mice are 
included for comparison.  (b) Vκ-RS rearrangement levels in κ+ splenic B cell subsets 
from C57Bl/6 (black bars, n=5), MRL/lpr (white bars, n=4), and NOD (gray bars, n=5) 
mice.  All PCR reactions were performed in duplicate.  Data are represented as fold 
difference (+s.e.m., * = p<0.05 and ** = p<0.01) relative to the average RS level in 





Figure 2-7: RS rearrangement levels in MRL/MpJ and NOR strains. (a) Vκ-RS 
rearrangement levels in B cell fractions of the MRL/lpr control strain, MRL/MpJ (n=4, 
white bars) compared to MRL/lpr (n=4, gray bars). (b) Vκ-RS levels in B cell fractions of 
NOR mice (n=4, white bars) compared to NOD mice (n=5, gray bars).  MRL/lpr and NOD 
data are the same data that are shown in Fig. 2-6.  Data are represented as fold 
difference (+s.e.m., * = p<0.05) relative to the average RS level in C57Bl/6 splenic 
B220+ IgM+ Igκ+ B cells (dashed line).  BM (bone marrow) and splenic B cell fractions are 






Figure 2-8:  RS rearrangement levels do not correlate with patient group 
demographics.  (a) iRS rearrangement levels in CD19+ 9G4- Igλ+ peripheral B cells from 
healthy controls (black circles, n=26), SLE patients (white squares, n=23), and T1D 
patients (gray triangles, n=25) compared to CD19+ Igκ/Igλ ratios.  (b) iRS rearrangement 
levels in CD19+ 9G4- Igλ+ peripheral B cells from healthy controls (black circles, n=26), 
SLE patients (white squares, n=23), and T1D patients (gray triangles, n=25) compared to 
subject age in years.  (c) Mean iRS rearrangement frequencies compared between male 
(n=17) and female (n=57) subjects (+s.e.m., p=0.84).  (d) Mean iRS rearrangement 
frequencies among Caucasian (n=45), African-American (n=18), and other (n=11, 
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includes Asian, Hispanic, and Native American) ethnic groups (+s.e.m., p=0.67).  Data 
are depicted as iRS rearrangement frequency per genome copy (r-values represent 





Figure 2-9: RS rearrangement levels are lower amongst SLE and T1D patients.  (a, 
b) iRS rearrangement frequencies as quantified in peripheral CD19+ 9G4- κ+ and CD19+ 
9G4- λ+ B cells, respectively.  Data represent the iRS levels in healthy control subjects 
(black circles, n=26), SLE patients (white squares, n=24 for κ+, n=23 for λ+), and T1D 
patients (gray triangles, n=25).  Mean values are depicted as horizontal lines.  The 10th 
percentile of iRS frequencies among control subjects is depicted as a dashed line.  (c) 
iRS rearrangement frequencies in CD19+ 9G4- κ+ peripheral B cells compared to 
frequencies in CD19+ 9G4- λ+ cell from healthy controls (black circles, n=26) and SLE 
 57 
and T1D patients (white squares, n=48).  All PCR reactions were performed in duplicate.  
Data are depicted as iRS rearrangement frequency per genome copy.  Trend lines are 
depicted for control (solid line, slope=5.4) and autoimmune patients (dashed line, 
slope=3.3; r-values indicate Spearman correlation coefficients, ** = p<0.01). 
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Table 2-1 
 Control SLE T1D 
Number of Subjects 26 24 25 
Average Age (years) 33.8 (22-52) 37.3 (21-55) 38.5 (19-69) 
% Femalea 0.88 0.88 0.56 
% Caucasianb 0.58 0.29 0.92 
% African-American 0.27 0.42 0.04 
% Other 0.15 0.29 0.04 
Average κ/λ Ratio (CD19+) 1.5 (1.1-2.3) 1.8 (1.0-4.0) 1.6 (0.8-2.4) 
Average B Cell Fraction 
(CD19+) 
0.11 (0.05-0.19) 0.10 (0.01-0.2) 0.10 (0.02-0.19) 
Average Absolute B Cell 
Count (per µl)c 
221±126 176±163 190±107 
 
Table 2-1:  Demographic comparison among subject groups.  a, bSignificant 
differences were found with respect to gender and race between the T1D group and 
control group (p<0.05 and p<0.01, respectively) as well as between the T1D and SLE 
groups (p<0.05 and p<0.001, respectively).  cAbsolute B cell counts were obtained by 
multiplying the white blood cell count (from the CBC) by the percentage lymphocytes 
(from the electronic differential) and by the CD19+ fraction and are listed as averages ± 
s.d.  Absolute B cell counts represent the average of 25 control subjects, 23 SLE 

























The text, figures, and experiments in this chapter were the work of Anil Panigrahi with 
the following exceptions. The reciprocal product isolation and characterization 
presented in Table 2 were performed by Hui Li of the Weigert Laboratory.  The 
measurement of Igλ+ B cells in Lyn-/- mice presented in Figure 3-5b was performed by 
Andrew Gross of the DeFranco Laboratory. 
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INTRODUCTION 
Receptor editing is the process of ongoing antibody gene rearrangement which 
results in the generation of new antibody specificities.  As seen in chapter 2, this critical 
tolerance mechanism may be aberrant in some autoimmune disease states, presumably 
permitting the development of autoreactive B cells that are capable of participating in 
autoimmune responses.  However, the precise mechanism responsible for initiating 
receptor editing remains to be clearly defined. 
Experiments by Hertz and Nemazee demonstrated that B cell receptor (BCR) 
ligation of bone marrow B cells in vitro results in upregulation of Rag mRNA, increased 
IgL rearrangement, and increased Igλ expression (Hertz and Nemazee 1997).  The 
authors concluded that receptor editing is actively promoted by BCR signaling triggered 
by autoantigens.  Further experiments by Retter and Nemazee supported this model.  In 
these experiments, they exploited B cells in which the rearrangement history was 
retained on the chromosome.  B cells that have inactivated Cκ by RS deletion, a common 
event in λ B cells (Durdik et al. 1984; Siminovitch et al. 1985), can harbor a Vκ-Jκ 
rearrangement on the Cκ-deleted allele. These Vκ-Jκ remnants were examined to 
determine if they contained in-frame (IF) rearrangements.  They observed an elevated 
frequency of IF rearrangement remnants and thus proposed that receptor editing is an 
active, self-antigen driven process (Retter and Nemazee 1998).  However, in this study 
they were unable to demonstrate that IF editing precursors were autoreactive. 
Alternatively, Behrens and colleagues contend that recognition of self-antigens 
by immature B cells may not directly regulate receptor editing, instead proposing that 
absence of basal surface immunoglobulin (Ig) signaling reinitiates a transcriptional 
program which results in editing rearrangements (Tze et al. 2005).  Indeed, loss of basal 
Ig signaling by Cre-mediated IgH deletion or by pharmacological blockade of tyrosine 
kinase signaling pathways both resulted in the upregulation of transcription factors 
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associated with earlier stages of B cell development, increased Rag transcription, and 
generation of new IgL rearrangements.  Additionally, the Behrens group reported that 
self-antigen was capable of downregulating surface BCR and initiating the “de-
differentiation” process (Schram et al. 2008).  However, it is also possible that 
insufficient basal BCR signaling of immature B cells could lead to secondary IgL 
rearrangement.  Thus, although these studies have improved our understanding of its 
regulation, a conclusive link between B cell autoreactivity and stimulation of receptor 
editing has yet to be demonstrated. 
To address this issue we analyzed remnants of IgL rearrangements that have 
been edited, but are still retained in the chromosome.  By examining these editing 
precursors in IgH transgenic mouse models where IgL specificities have been extensively 
characterized, we are able to determine if autoreactive light chains are edited more 
often.  Additionally, the effect of aberrant BCR signaling on receptor editing was studied 
to discern whether positive BCR signals are required for efficient editing.  Furthermore, 
the influence of genetic polymorphisms on editing was assessed in the hope of 
identifying key factors responsible for decreased RS rearrangement frequencies 
observed in the context of autoimmunity. 
 
RESULTS 
RS rearrangement levels differ between autoreactive and non-autoreactive B cells 
It is unclear how or if receptor editing is linked to autoreactivity.  Editing is 
driven either by the potential of the antibody heavy light chain pair to form 
autoantibodies (active model), or it occurs stochastically without regard for receptor 
specificity (passive model).  To distinguish between active and passive editing, the RS 
rearrangement assay for estimating receptor editing frequencies (described in Chapter 
2) was applied to the 56R mouse model, where the B cell repertoire has been 
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characterized extensively (Li et al. 2001; Sekiguchi et al. 2006; Liu et al. 2007).  The 56R 
mouse carries a site-directed transgene (sd-tg) encoding an anti-DNA specific IgH.  
Using B6.56R+/- mice, one can distinguish B cells with an autoreactive IgH (IgMa+, mostly 
56R expressing) and endogenous (IgMb+, 56R-) B cells (Fig. 3-1a).  56R-expressing B 
cells have a restricted light chain repertoire consisting of only a handful of light chains, 
termed editors, because they modify or reduce DNA binding (Li et al. 2001; Sekiguchi et 
al. 2006; Liu et al. 2007).  This restriction in light chain usage could arise if 56R B cells 
with non-editor light chains were counter-selected or if B cells with non-editor light 
chains were subjected to more receptor editing.  The former alternative predicts equal 
levels of RS rearrangement in IgMa+ and IgMb+ cells, whereas the latter predicts higher 
levels of RS rearrangement in IgMa+ B cells.  Consistent with an active model of receptor 
editing, a two-fold increase in RS rearrangement levels was observed in IgMa+ B cells 
(Fig. 3-1b). 
 
Recovery of editing precursors from splenic B cells 
The observation that RS rearrangement levels are elevated among 56R+ B cells 
strongly suggests that autoreactivity plays a role in stimulating receptor editing.  
However, from this experiment alone the autoreactive specificity of 56R+ cells bearing 
RS rearrangements cannot be confirmed.  Thus, in order to more precisely define the 
original specificity of edited cells, a genetic approach focused on light chain precursor 
rearrangements was used.   
The analysis of a lymphocyte’s rearrangement history can provide insights into 
mechanisms that regulate ongoing V(D)J recombination.  Different models predict 
different frequencies of productive (in-frame, IF) rearrangement precursors (Table 3-1).  
If feedback inhibition of rearrangement by a functional heavy light chain pair (H/L-STOP, 
(Alt et al. 1984; Cohn and Langman 1990)) were immediate and irreversible in all B cells, 
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no rearrangement precursors would be IF.  The existence of receptor editing argues 
against this model since alleles with functional rearrangements can undergo further 
rearrangement (Harada and Yamagishi 1991; McCormack et al. 1993; Retter and 
Nemazee 1998; Holman et al. 2003).  Conversely, if cells underwent secondary 
rearrangement without regard for the specificity or functional status of the primary 
rearrangement (the “leaky” H/L-STOP model), one would expect the fraction of IF 
rearrangement precursors to be approximately 33% (Harada and Yamagishi 1991).  Yet, 
the complete absence of an H/L-STOP signal is unlikely, given experiments that 
demonstrate inhibition of further rearrangement (allelic exclusion) by antibody 
transgenes (Ritchie et al. 1984).  The high frequency of cells with κ+/κ0 genotypes also 
favors an active H/L-STOP (Coleclough et al. 1981). 
Vκ editing can occur by deletion, resulting in the production of an episome (Fig. 
3-2a), or by inversion, resulting in a reciprocal product (RP, Fig. 3-2b).  A third editing 
pathway is RS deletion (Fig. 3-2c).  Previous studies have analyzed V-J joins present on 
episomes (Fig. 3-2a, (Harada and Yamagishi 1991; McCormack et al. 1993; Holman et 
al. 2003)), however, these products are not maintained in cells and cannot be linked to a 
defined IgH chain.  Therefore, we focused on rearrangement precursors that were 
retained on the chromosome.  Of the two chromosomally retained pathways (inversion 
and RS deletion), RS deletion is more amenable to screening large numbers of 
rearrangements because the deleted allele can be identified on a short stretch of the 
chromosome (Fig. 3-2b).  The editing rearrangement of interest utilizes a cryptic 
recombination signal sequence (RSS) within the Jκ-Cκ intron (iRS) which recombines with 
the κ locus Recombination Segment (RS), located 25kb downstream of Cκ (Durdik et al. 
1984; Siminovitch et al. 1985).  The resulting rearrangement product lacks Cκ (thereby 
inactivating the locus), but retains the Vκ-Jκ rearrangement. 
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To recover Vκ-Jκ rearrangements on RS deleted kappa alleles, we purified 
genomic DNA from spleen fragments of homozygous 3H9 (3H9+/+) and 3H9/56R 
(56R+/+) IgH sd-tg mice (Erikson et al. 1991; Chen et al. 1995).  The presence of the sd-
tg on both alleles may reduce the chances of successful IgH chain editing, which could 
confound interpretation of antibody specificity.  Using a PCR strategy similar to what has 
been described previously (Dunda and Corcos 1997; Retter and Nemazee 1998), we set 
up two types of assays to recover Vκ-Jκ rearrangements on RS deleted kappa alleles (Fig. 
3-2b).  The first assay used a degenerate Vκ primer, Vs, to recover Vκ-Jκ 
rearrangements without regard for their specificity (Schlissel and Baltimore 1989).  The 
second assay used editor-specific Vκ primers (Vκ12 in 3H9 and Vκ38c in 56R) to 
address if editor rearrangements could themselves be edited.  We reasoned that an 
editor-specific rearrangement assay was necessary to recover adequate numbers of 
informative rearrangements in a model such as 56R, because nearly all functional Vκ 
genes are non-editors. 
As depicted in Figure 3-2b, Igκ locus inactivation by RS deletion can occur via 
two major pathways, direct Vκ to RS rearrangement or rearrangement of the Jκ-Cκ intron 
recombination signal sequence, iRS, to RS.  Only the latter pathway retains the primary 
Vκ-Jκ rearrangement on the chromosome.  Unfortunately, iRS-RS rearrangements are 
harder to recover than Vκ-RS rearrangements, in part because the iRS-RS PCR product is 
several hundred base pairs larger.  The PCR also may have introduced a selection bias in 
favor of rearrangements to Jκ5 because such Vκ-Jκ rearrangements are the smallest in 
size and most readily amplified.  Alternatively, it is possible that rearrangements to Jκ5 
(the last Jκ segment available for rearrangement in the Jκ cluster) are more common on 
RS deleted alleles. 
In estimating the frequency of IF editing precursors, we only counted 
rearrangements that were clonally independent.  Several steps were taken in order to 
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ensure clonal independence.  First, DNA was isolated from several mice per genotype.  
Second, each spleen was cut into fragments and DNA was extracted separately from 
each fragment.  Third, junctional diversity of the iRS-RS rearrangement was used to 
identify unique rearrangements in cases where the Vκ-Jκ junctions appeared similar.  
While CDR3 diversity at Igκ is limited, junctional diversity at RS is considerable and 
consists mostly of small deletions (Fig. 3-3). 
 
Analysis of editing precursors 
By comparing the frequency of IF editing precursors among editor Vκ 
rearrangements to the IF frequency among non-editor rearrangements, we can 
determine if the specificity of the primary rearrangement influences whether or not 
editing occurs.  If autoreactivity stimulates receptor editing, we would expect fewer IF 
rearrangements among editor Vκ rearrangements than among non-editor Vκ 
rearrangements.  In 56R+/+ mice, 3 of the 11 (27%) Vκ-Jκ rearrangements using the 
editor Vκ38c were in-frame (Fig. 3-4a).  This frequency is similar to the 33% predicted 
by a random editing process and is higher than expected if receptor editing is 
stimulated by autoreactivity.  Indeed, when non-editor Vκ12 rearrangements were 
examined in 56R+/+ mice, 8 out of 32 (25%) rearrangements were IF (Fig 3-4c).  The 
similarity in IF frequencies between editor and non-editor rearrangements in 56R 
suggests that either editing occurs without respect to BCR specificity or that the 
difference in specificities between editors and non-editors is not significant in the 
context of 56R.  As the 56R heavy chain is highly specific for DNA, it is plausible that 
even 56R antibodies utilizing editor light chains still retain autoreactivity (see 
discussion). 
When Vκ12 rearrangements are studied in 3H9+/+ mice, where they act as 
editors, 4 of 22 (18%) editing precursors were found to be in-frame (Fig 3-4b).  This 
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frequency is nearly half of the 33% predicted if editing occurred randomly and suggests 
that these rearrangements are disfavored as substrates for receptor editing.  Consistent 
with this interpretation is the fact that the 3H9 heavy chain confers a weaker anti-DNA 
reactivity than the 56R heavy chain implying that editor light chains may be more 
successful in abrogating autoreactivity when paired with 3H9 and thus accounting for 
the difference in IF frequencies between editors in 56R and 3H9 mice.  The low 
frequency of IF editor rearrangement precursors is not due to inefficient recombination 
of editor Vκs because the IF rearrangement frequency of the same Vκ seems to depend 
upon the IgH chain context: 18% of Vκ12 (editor) rearrangements in 3H9 are IF 
compared to 25% of Vκ12 rearrangements (non-editor) in 56R.  However, this difference 
is not statistically significant due to the small sample size (p=0.4); demonstrating 
significance given the current frequencies would require characterization of over 200 
precursors.  Nevertheless, the result indicates a trend toward a decreased IF frequency 
among non-autoreactive editing precursors. 
A caveat to these data is that despite having the sd-tg on both IgH chain alleles, 
the transgene could still be edited (Yunk et al. 2009).  To exclude this possibility, 56R+ 
hybridomas were analyzed for the presence of functional Vκ-Jκ joins on RS deleted Igκ 
alleles.  Five out of ten (50%) RS deleted Vκ-Jκ rearrangements were IF and all 
rearrangements were to non-editor Vκs (Fig. 3-4d).  When the hybridoma and spleen 
data are combined, 31% (13/42) of non-editor rearrangements were found to be IF. 
 
Identifying editing precursors among reciprocal products 
One potential limitation to the data obtained from spleen DNA and hybridoma 
panels derived from 3H9 and 56R mice is that Vκ-Jκ rearrangements on the second 
kappa allele could influence editing on the first.  Therefore we characterized hybridoma 
reciprocal products isolated from mice hemizygous for Jκ-Cκ deletion (JCκ-/+; (Chen et 
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al. 1993)).  These mice also possess heavy chain site-directed transgenes (sd-tgs) 
3H9/GL, 3H9 or 56R (Erikson et al. 1991; Chen et al. 1995; Li et al. 2003). 
For a hybridoma to have an informative reciprocal product (RP), it must satisfy 
two criteria.  First, it must retain the heavy chain transgene (tg+).  For 3H9/GL-κ+/+, 3H9, 
and 56R this is usually the case (83-95% of hybridomas are tg+) (Erikson et al. 1991; 
Chen et al. 1995; Li et al. 2003).  Second, the orientation of the Igκ chain editor must be 
such that the RP is retained on the chromosome.  For example, when the editor, Vκ12, 
replaces a Vκ-Jκ1 rearrangement by inverting to Jκ2, we can characterize the Vκ-Jκ1 RP 
because it is retained on the chromosome (Fig. 3-2c).  The germline orientations of all 
Vκs are known (Thiebe et al. 1999), so the post-rearrangement status of a Vκ can be 
inferred.  We chose to focus mainly on Jκ2 editor rearrangements because 
rearrangements to downstream Jκ segments (Jκ4 or Jκ5) could arise through more 
complex rearrangement pathways.  The study of Jκ2 editors was facilitated by having a 
large collection of hybridomas that were edited by rearrangement to Jκ2. 
To determine the fraction of IF RP, partial sequences of RP to Jκ1 were obtained 
by PCR with Vs and Jκ1inv primers (Fig. 3-2c).  These sequences include the Vκ-Jκ1 
junction, allowing assignment of the reading frame.  Our analysis of Vκ-Jκ1 
rearrangements in RP of heavy chain tg+ JCκ+/- hybridomas revealed that 5 out of 13 
(38%) were IF (Table 3-2).  If autoreactive cells had a higher death rate than cells with 
non-self rearrangements, one would predict fewer rather than more IF RPs (Table 3-1).  
Although our analysis revealed that RPs are rare among peripheral B cells, the 
abundance of functional rearrangements in RS deleted alleles and chromosomal RPs in 
this study is consistent with a high frequency of autoreactivity in the pre-edited 




Lyn-mediated inhibition of BCR signaling does not influence receptor editing 
If receptor editing is actively stimulated by BCR signaling that results from 
autoantigen ligation, enhanced BCR signaling may lead to increased receptor editing by 
decreasing the required signaling threshold.  Alternatively, enhanced signaling may lead 
to increased deletion of immature autoreactive B cells and consequently result in lower 
levels of editing among survivors (Cornall et al. 1998; Braun et al. 2000).  To address 
this issue, RS rearrangement levels were measured in bone marrow and splenic B cells 
from Lyn-/- mice.  Lyn is a Src family tyrosine kinase that not only phosphorylates ITAMs 
of BCR components, but also engages immunoreceptor tyrosine-based inhibitory motifs 
(ITIMs) on B cell co-receptors which ultimately leads to a reduction in BCR signaling. 
The absence of Lyn activity did not affect RS recombination in pre-B cells (Fr. D), 
as RS rearrangement levels were similar to those in wild-type mice (Fig 3-5a).  
Additionally, loss of Lyn inhibition did not alter the decrease in RS levels seen at the 
immature B cell stage (Fr. E) indicating that the loss of RS+ cells at this transition is 
independent of Lyn.  Similarly, RS rearrangement levels among splenic transitional B 
cells were unaffected (Fig 3-5a).  Taken together these data suggest that Lyn is not 
required for normal receptor editing and does not substantially influence tolerance 
checkpoints during B cell development.  Consistent with this interpretation, frequencies 
of Igλ+ B cells decreased normally through B cell development in Lyn-/- mice, 
demonstrating that these cells were appropriately counter-selected (Fig 3-5b). 
 
Autoimmune associated polymorphism in PTPN22 does not affect receptor editing 
Several studies have discovered that a single nucleotide polymorphism (SNP 
1858C to T) in the gene encoding the protein tyrosine phosphatase N22 (PTPN22, also 
known as lymphoid tyrosine phosphatase, Lyp) is correlated with multiple autoimmune 
diseases in humans, including type-1 diabetes (T1D) and systemic lupus erythematosus 
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(SLE) (Bottini et al. 2004; Kyogoku et al. 2004).  The 1858C/T SNP causes a 
conformational change in the interaction site of PTPN22 with the protein tyrosine kinase 
CSK and results in increased inhibition of TCR signaling (Cloutier and Veillette 1999; 
Vang et al. 2005).  PTPN22 is also expressed in B cells, however, its role in B cell 
signaling and activation is still being determined.  Interestingly, the PTPN22 1858T allele 
is prevalent in two patient groups in which we observed reduced receptor editing levels 
(SLE and T1D, see Chapter 2).  Furthermore, Buckner and colleagues recently reported 
that the PTPN22 SNP resulted in decreased numbers of memory B cells which 
additionally displayed decreased responses to BCR stimulation (Rieck et al. 2007).  Thus, 
although a role for PTPN22 in B cell development has not been established, it may be 
possible that increased inhibition of BCR signaling in immature B cells may hinder 
receptor editing by disrupting autoantigen mediated stimulation. 
To investigate the role of the PTPN22 1858T variant on receptor editing, healthy 
individuals were separated based upon their SNP status and the degree of RS 
rearrangement in peripheral B cells of each group was assessed.  Unlike the previous 
experiments, none of the individuals tested had signs of autoimmunity.  Therefore if the 
presence of the SNP correlated with decreased RS rearrangement, it would additionally 
suggest that the RS assay may be useful as a predictor of autoimmune disease 
development.  However, no difference in RS rearrangement frequencies between 
individuals carrying the disease-associated 1858T allele and those with the more 
common 1858C allele were observed in mature peripheral B cells (CD19+ CD24low 
CD38int, Fig. 3-6a).  Moreover, RS rearrangement levels in both Igκ+ and Igλ+ B cells 
were similar to levels from the healthy individuals described in Chapter 2.  Despite this 
finding, it is possible that defects in receptor editing may not be detectable among 
mature B cells, as peripheral tolerance mechanisms in these healthy individuals may 
eliminate minimally edited B cells from the circulation.  To address this issue, RS 
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rearrangement levels of immature B cells (CD19+ CD24hi CD38hi) from the same 
individuals were assayed.  Similar to mature B cells, RS levels were found to be 
equivalent between the two SNP groups (Fig. 3-6a) indicating that the 1858T variant 
does not affect rearrangement levels among immature peripheral B cells.  Additionally, 
no consistent intra-individual changes between RS frequencies in immature and mature 
B cells were detected (Fig. 3-6b), suggesting that if increased PTPN22 activity leads to 
the development of minimally edited B cells, such cells are likely deleted in the bone 
marrow or prevented from entering the peripheral circulation. 
 
NOD Idd loci 3 and 5 do not contribute to decreased RS rearrangement levels 
As discussed in Chapter 2, NOD mice, a model of type-1 diabetes, demonstrate 
decreased levels of RS rearrangement suggesting that defects in receptor editing may 
contribute to their disease susceptibility.  The cause of the decrease in editing is likely 
complex, as extensive investigation into the genetic basis of diabetes in these mice has 
revealed over 20 Idd (insulin-dependent diabetes) loci that contribute to disease 
(Ridgway 2006).  However, in addition to insulitis, NOD mice also experience exocrine 
gland dysfunction resulting from autoimmune damage of salivary and lacrimal glands.  
Moreover, this autoimmune exocrinopathy (AEC, also known as Sjögren’s syndrome) is 
correlated with Idd5 and Idd3, located on chromosomes 1 and 3, respectively (Brayer et 
al. 2000).  Importantly, when these loci were bred onto C57Bl/6 mice, the resulting AEC 
mice display a Sjögren’s syndrome-like phenotype, with lymphocytic infiltration of 
exocrine glands, decreased secretory function, and serum autoantibody production (Cha 
et al. 2002).  Given the shared B cell involvement in both disease processes and the 
common genetic loci between NOD and AEC mice, we hypothesized that receptor editing 
may also be altered in AEC mice and if so, could help restrict the search for novel 
elements that regulate receptor editing. 
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Therefore RS rearrangement levels were measured in 3-month old AEC mice for 
comparison with NOD mice to determine if impaired receptor editing is also correlated 
with Idd3 and 5 (Fig. 3-7).  In contrast to NOD mice that display decreased RS 
rearrangement levels in the majority of B cell subsets tested, AEC mice displayed RS 
levels similar to wild-type C57Bl/6 mice in all subsets.  This result suggests that genes 
located in Idd3 and Idd5 do not directly influence receptor editing levels or at the least 
require additional defects in order to affect RS rearrangement. 
 
DISCUSSION 
Receptor editing is a crucial tolerance mechanism of developing B cells, however, 
the precise regulation of this process is still unclear.  Mounting evidence suggests that 
editing occurs in response to autoreactivity of immature B cells, however, it is also 
possible that increased residence time of B cells in the bone marrow may lead to 
prolonged Rag activity and secondary IgL rearrangement.  If autoreactivity drives 
receptor editing, then B cells known to express anti-self BCRs should harbor signs of 
more extensive IgL rearrangement.  Indeed, an increased RS rearrangement frequency 
was observed in B cells with autoreactive heavy chains (56R+ B cells) relative to those 
with wild-type heavy chains.  Because RS rearrangements do not encode a protein that 
can be selected, this result indicates that the presence of an autoreactive heavy chain 
increases the likelihood of ongoing light chain rearrangement and is consistent with 
other reports favoring an active, autoantigen driven model of receptor editing (Hertz 
and Nemazee 1997; Schram et al. 2008).  However, additional experiments are required 
to rule out developmental changes caused by expression of a preformed IgH which 
could indirectly lead to increased RS rearrangement (see Chapter 4). 
Additional IgL rearrangement can also occur if Vκ-Jκ recombination results in a 
non-functional light chain (out-of-frame rearrangement).  However, since feedback 
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inhibition (H/L STOP) is known to be incomplete, rearrangement can continue despite 
the presence of functional, in-frame IgL rearrangements.  An active model of editing 
would predict a bias among these rearrangements, as autoreactive light chains should 
be edited more often and thus be more prevalent among edited IF IgL rearrangements.  
To test this prediction, a detailed genotypic analysis of receptor editing precursors in 
the form of RS deleted and inverted (RPs) Vκ-Jκ rearrangements was performed.  B cells 
from three different heavy chain knock-in mouse models (3H9 GL, 3H9, and 56R) were 
studied.  By fixing the heavy chain, it was possible to make inferences regarding the 
reactivity (autoreactive vs. non-autoreactive) of the edited light chain rearrangements.  
The analysis revealed a significant number of IF edited rearrangements and, among IF 
rearrangement precursors, an enrichment of autoreactive light chains. 
In support of an autoreactivity-driven model, we observed a trend toward an 
increase in the IF frequency of Vκ12 precursors when acting as non-editors (25%) 
compared to editors (18%).  The difference in IF frequency between these two situations 
indicates that autoreactive specificities influence receptor editing and is incompatible 
with a model of random secondary rearrangement (“leaky” H/L STOP).  In fact, if 
autoreactive rearrangements led to deletion of the B cell, then the predicted frequency 
of IF autoreactive precursors should be less than that of non-self precursors.  That the 
IF frequency of non-editor Vκs is higher supports a model in which cells with 
autoreactive Vκs are favored.  Additionally, in surveying editing precursors from heavy 
chain transgene expressing hybridomas, we found an even greater frequency of IF 
rearrangements (50%), all of which involved non-editor light chains.  Among RS deleted 
κ alleles in wild type mice, Retter and Nemazee found that 47% were IF.  The abundance 
of IF Vκ-Jκ precursors in both of these studies is incompatible with the strict H/L-STOP 
model of light chain rearrangement (Table 3-1).  It is also inconsistent with leaky H/L-
STOP model, which would predict that no more than 33% of edited Vκ-Jκ rearrangements 
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would be IF.  Taken together these findings support a model where autoreactive 
rearrangements are selectively targeted for editing, and along with the high IF 
frequencies of non-editor precursors, lend further support for the finding that the 
fraction of the normal B cell repertoire that is potentially autoreactive is high 
(Wardemann et al. 2003). 
Despite the findings in support of an autoreactivity-driven model of receptor 
editing, examination of editor precursor rearrangements in 56R+/+ mice revealed 
significantly higher IF frequencies than expected.  Out of 11 Vκ38c rearrangements 
isolated, 3 (27%) were found to be IF.  This frequency is 1.5 times greater than the IF 
frequency of editors in 3H9+/+ mice and much closer to the 33% frequency predicted by 
a random model of receptor editing.  There are several possibilities than can account for 
this IF frequency.  First, as described previously, the method of recovering editing 
precursors after RS rearrangement can lead to biases toward smaller precursor 
rearrangements that often involve Jκ5.  This bias could influence the IF frequency if Jκ 
usage altered the specificity of the light chain as an editor.  Indeed, previous studies 
have demonstrated that Vκ38c editors in 56R tend to have a restricted Jκ usage (Li et al. 
2001; Sekiguchi et al. 2006).  This restriction, however, is generally to Jκ4 or Jκ5 and as 
all of the Vκ38c precursors isolated from 56R+/+ were rearranged to Jκ5, it is likely that 
the IF precursors would have functioned appropriately as editors. 
Alternatively, the additional arginine residue introduced in the 56R heavy chain 
may make editor light chains ineffective in fully nullifying the anti-DNA specificity.  
Thus, despite being expressed by mature peripheral B cells, editor light chains in 56R 
may still retain autoreactivity.  Weigert and colleagues tested monoclonal antibodies 
(mAbs) from 56R hybridomas and found that despite incorporating editor light chains, 
several bound dsDNA (Li et al. 2001).  In their hybridoma survey, they observed that 56R 
antibodies mainly used three different editor light chains: Vκ20, Vκ21D, and Vκ38c.  
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Interestingly, binding studies revealed that although the majority of 56R antibodies 
associated with Vκ20 or Vκ21D did not bind dsDNA, 4 out of 7 hybridomas expressing 
the editor Vκ38c still bound DNA.  In these cases DNA reactivity was attributed to allelic 
inclusion at λ, as the hybridomas were positive for λ1 rearrangements by PCR and ELISA.  
A mechanism for generating this allelic inclusion has been proposed by Khan et al. 
whereby Vκ38c associated 56R heavy chains bind not only DNA, but also a Golgi related 
antigen (Khan et al. 2008).  A consequence of this reactivity is sequestration of IgM 
molecules from the cell surface, which may allow for continued light chain 
rearrangement and allelic inclusion.  Indeed, marginal zone B cells, a population thought 
to be enriched for allelically included B cells (Li et al. 2002), demonstrated increased 
levels of Vκ38c rearrangement.  The findings that autoreactivity and allelic inclusion are 
associated with Vκ38c light chains in 56R mice provide a compelling explanation for the 
high IF frequencies observed among Vκ38c editing precursors.  Although peripheral B 
cells from 56R mice express Vκ38c light chains, Vκ38c does not appear to function as a 
true editor in the sense of abrogating autoreactivity.  Consequently, the high IF 
frequency of Vκ38c precursors is not inconsistent with an autoreactivity driven model 
for receptor editing and in fact may support it.  Analysis of Vκ20 or Vκ21D precursor 
rearrangements in 56R may prove more informative as these light chains have been 
shown to reduce self-reactivity (Liu et al. 2008) and thus could provide more conclusive 
support for an autoreactivity-induced model of editing. 
Overall, 33% of edited autoreactive rearrangements characterized in this study 
were in-frame.  Moreover, when 56R-expressing hybridomas were surveyed without 
respect to Vκ usage, 50% of editing precursors were in-frame.  This frequency is similar 
to that observed by Retter and Nemazee in their survey of wild-type λ-expressing 
hybridomas, where they found that 47% of edited rearrangements were in-frame.  
However, the Hogquist laboratory reported a lower frequency of in-frame 
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rearrangements (~26%) in excision circles from HY TCRβ transgenic mice (Holman et al. 
2003).  A key difference between these data sets is the types of rearrangements each 
represent.  Unlike inverted or RS deleted rearrangements, excision circles are not 
maintained through replication cycles.  Consequently, the joins on these episomes 
represent a full spectrum of rearrangements, including those in cells that will not pass 
negative selection.  Thus the low IF frequency among episomal rearrangements suggests 
that the rearrangement process itself is not biased towards a higher IF frequency.  
Rather, B cells that successfully edit (pass selection) have a higher proportion of IF 
editing rearrangement precursors.  This implies that B cells with productive 
rearrangements are favored.  Yet this favoritism is likely not only due to having an IF 
primary rearrangement, since a potential decrease in IF frequencies of editor Vκs (18%) 
suggests a bias based upon specificity.  One possibility to account for this difference is 
the positive selection of autoreactive receptors before editing takes place.  This idea is 
supported by recent studies from the Jumaa lab where expression of polyreactive BCRs 
lead to enhanced survival and expansion of immature B cells (Meixlsperger et al. 2007; 
Kohler et al. 2008). 
Thus, it appears that selection acts upon autoreactive Vκ-Jκ rearrangements 
prior to tolerance induction and again after editing.  But why would it be useful to favor 
the production of what is usually an autoreactive BCR only to modify or abrogate its 
auto-specificity in a subsequent rearrangement step?  The generation of B cells that can 
recognize self may help optimize the immune repertoire to recognize altered self.  This 
argument has long been used to rationalize positive selection in T cells (Jameson et al. 
1995).  Yet the molecular mechanism of achieving optimal recognition of altered self is 
still poorly understood.  One potential function of the antibody light chain (or TCRα) 
editing is to fine-tune the repertoire so that it is weakly anti-self.  Self-specificity could 
be maintained by the dominant influence of the heavy chain, which is then modified to a 
 76 
lesser degree by light chain editing.  Alternatively, editing could result in light chain 
allelic inclusion, therefore promoting multi-reactivity that could be beneficial in 
detecting antigens common to various pathogens. 
If receptor editing is indeed stimulated by autoantigen mediated BCR signaling, 
perturbation of the signaling pathway should influence the degree of receptor editing.  
To address this question, the effect of two signaling molecules on receptor editing was 
assessed.  Lyn is a tyrosine kinase that normally functions to inhibit BCR signaling.  
However, Lyn-/- B cells did not show differences in receptor editing levels compared to 
wild-type B cells, indicating that Lyn-mediated inhibition is not required for effective 
regulation of receptor editing.  Interestingly, Lyn-/- mice develop a lupus-like phenotype 
with increased serum IgM levels, serum autoantibodies, and glomerulonephritis (Hibbs 
et al. 1995).  These defects appear to be the result failed peripheral tolerance 
mechanisms, as receptor editing and deletion of immature B cells are intact (Gross et al. 
2009).  Similarly, a polymorphism in PTPN22, which is found in high frequencies among 
humans with autoimmune disease, did not affect receptor editing as measured by RS 
rearrangement.  This phosphatase serves to inhibit TCR signaling in T cells and may play 
a similar role in B cells, but the increased activity of 1858T variant did not affect RS 
rearrangement frequencies. 
As both of the molecules serve to temper positive BCR signaling, these results 
suggest that either Lyn and/or PTPN22 do not function in immature B cells or that the 
regulation of receptor editing does not involve positive BCR signaling.  If the latter 
alternative is true, it suggests that receptor editing is not directly stimulated by BCR 
signaling.  However, this does not preclude receptor editing from occurring in response 
to autoantigen ligation.  As proposed by Behrens and colleagues, BCR ligation in 
immature B cells may lead to loss of BCR surface expression and de-differentiation of 
immature B cells and induction of secondary IgL rearrangement.  This back-
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differentiation process appears to result from loss of basal signaling from surface BCR 
(Tze et al. 2005), suggesting that positive signaling is not required for receptor editing.  
Consistent with the results from the Lyn and PTPN22 studies, Schram et al. found that 
mimics of positive BCR signaling in immature B cells impaired receptor editing rather 
than promoting it (Schram et al. 2008). 
In addition to investigating the nature of the stimulus for receptor editing, the 
studies presented here attempted to identify genetic defects that are responsible for 
decreased receptor editing observed in conditions of autoimmunity.  To that end RS 
rearrangement levels in the AEC mouse strain, a model of Sjögren’s syndrome, were 
characterized.  AEC mice develop autoimmune disease but only have 2 of the over 20 
Idd loci from the NOD strain correlated with development of diabetes.  If AEC mice also 
demonstrated defects in RS rearrangement it could focus the search for additional 
factors that influence receptor editing.  However, RS rearrangement levels in these mice 
were found to be equivalent to those in wild-type mice.  AEC mice carry the NOD Idd3 
locus, located on chromosome 3, which has been implicated in lymphocyte dysfunction.  
Specifically, this locus has been attributed with defects in T cell suppression likely due 
to impaired IL-2 production (Yamanouchi et al. 2007).  Additionally, the other NOD 
derived locus expressed in AEC mice, Idd5 on chromosome 1, has been implicated in 
aberrant T cell activation.  Mice carrying the NOD Idd5 allele, demonstrate surface 
expression of an altered CTLA-4 isoform, an important suppressor of TCR signaling, 
which accelerates development of T1D (Luhder et al. 1998; Wicker et al. 2004).  Thus it 
appears that the NOD-derived Idd loci present in AEC mice likely cause aberrant T cell 
activation which contributes to development of autoimmunity (Lundholm et al. 2006).   
Despite the evidence for T cell effects, Idd5 has also been reported to affect the 
diabetogenic activity of B cells in NOD mice.  Previous studies have found that T1D in 
NOD mice develops in part due to B cell intrinsic effects (Serreze et al. 1996; 
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Noorchashm et al. 1997).  NOD B cells were found demonstrate defects in clonal 
deletion of immature B cells and impaired anergy (Silveira et al. 2004).  Interestingly, 
NOR mice, which display decreased RS rearrangement despite being diabetes resistant, 
were found to anergize autoreactive B cells normally.  Moreover, this effect was found to 
correlate with differences in Idd5 and Idd9/11 (Silveira et al. 2006).  As both NOD and 
NOR mice displayed decreased levels of RS recombination, this indicates that the B cell 
effect of NOD Idd5 likely does not influence receptor editing and is consistent with the 
results from AEC mice.  Taken together these results suggest that Idd3, 5, and 9/11 do 
not influence receptor editing. 
The results described here are consistent with a model of receptor editing that is 
biased towards autoreactive BCRs.  Analysis of BCR signaling mediators, however, 
suggests that positive BCR signals may not be required for effective receptor editing.  
Furthermore, several genetic polymorphisms correlated with autoimmune disease were 
found not to influence receptor editing, indicating that additional factors are responsible 
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Figure 3-1:  RS rearrangements are increased in B cells expressing an autoreactive 
heavy chain in self-tolerant mice.  (a) Flow cytometry of splenic follicular (B220+, 
AA4.1-, CD23+) κ+ B cells from heterozygous B6.56R mice depicting separation of B cells 
by immunoglobulin heavy chain allotype.  (b) Vκ-RS rearrangement frequencies 
measured in follicular B cells expressing endogenous heavy chains (IgMb+, black bar) and 
the 56R anti-DNA heavy chain (IgMa+, gray bar) from heterozygous B6.56R mice (n=4).  
All PCR reactions were performed in duplicate.  Data are presented as fold difference 
relative to the average RS level in C57Bl/6 splenic B220+ IgM+ κ+ B cells (dashed line).  
Error bars indicate +s.e.m. and the * denotes p<0.05 by one-tailed Student's t-test.  A 
one-tailed statistical test was chosen because an active model of receptor editing 
predicts an increase in RS rearrangement levels among 56R expressing B cells, while a 








Figure 3-2: Multiple editing rearrangement pathways are possible at the murine 
Igκ locus.  Shown are idealized murine Igκ loci with 3 Vκ segments, the four functional 
Jκ segments, Cκ, the intronic recombination signal sequence (iRS) and the RS 
downstream of Cκ.  Exons are denoted with boxes, introns with lines and recombination 
signal sequences (RSS) by triangles.  The open triangles denote RSSs with 12 bp spacers 
and the shaded RSSs with 23 bp spacers.  Dashed lines denote the rearranging gene 
segments.  Small arrows denote primers used in RS and Vκ-Jκ genotyping assays.  
Figure (a) depicts deletional rearrangement generating an excision product.  When 
deletional rearrangement occurs, the intervening DNA is lost on an episome 
(represented by a circle).  Figure (b) represents deletional rearrangement involving the 
iRS and RS results in an inactivated Igκ allele (Cκ is released on an episome).  This 
inactivated allele retains a Vκ-Jκ precursor rearrangement that can be analyzed by Vκ-RS 
PCR.  Figure (c) portrays secondary rearrangement by inversion which retains the 
precursor rearrangement on the chromosome.  Inversions can be typed by PCR by 
scoring for rearrangements that amplify with a proximal Jκ primer but fail to amplify 





Figure 3-3: iRS-RS junctions demonstrate a high degree of diversity.  iRS-RS 
rearrangements were cloned and sequenced from genomic spleen DNA of 56R+/+, 
3H9+/+ mice and from 56R+ hybridomas.  Mouse or clone numbers are listed along with 
the identity of Vκ genes edited by iRS-RS rearrangement.  RS junctional deletions are 
aligned relative to the junction predicted by RSS sequences.  Nucleotides attributable to 





a     56R Vκ38c-Jκ5 
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b     3H9 Vκ12/13-Jκ5 
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d    56R Hybridoma Vsh-Jκ5 
 
Figure 3-4: A high frequency of editing precursors on RS deleted kappa alleles are 
in-frame.  Genomic DNA from 56R+/+ or 3H9+/+ mouse spleens (a-c) or from 
hybridomas (d) was subjected to PCR using primers situated in Vκ (38c, 12 or Vs) and RS 
(see materials and methods).  Amplicons over 1.2kb in size were cloned and sequenced 
in both directions.  Figures (a-c) show the mouse genotype, animal number, Vκ-Jκ 
junction and whether the junction is in frame (I/F) or out of frame (O/F).  Figure (d) 
shows the Vκ-Jκ5 rearrangements recovered from RS deleted alleles in 56R+ LPS and 
spontaneously fused hybridomas. 
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Figure 3-5 
a       b 
 
Figure 3-5: Absence of Lyn does not impair receptor editing and clonal deletion of 
immature B cells.  (a) Vκ-RS rearrangement levels were measured in genomic DNA from 
Igλ- bone marrow (Fr. D and Fr. E) and splenic (T1 and Fo) B cell populations from Lyn-/- 
and wild-type (WT) mice.  Two mice were analyzed per experiment and results from two 
separate experiments are depicted.  All PCR reactions were performed in duplicate.  Data 
are represented as fold difference relative to the mean RS level in wild-type Igλ- 
follicular B cells.  (b) The frequency of Igλ+ B cells in bone marrow (Fr. E) and splenic (T1, 
T2, T3, Fo) B cell populations from Lyn-/- (n=10) and wild-type (n=11) as assessed by 









Figure 3-6: The PTPN22 1858T variant does not affect receptor editing in healthy 
individuals.  (a) iRS rearrangement frequencies as quantified in genomic DNA from 
peripheral immature (CD19+ CD24hi CD38hi, left) and mature (CD19+ CD24low CD38int, 
right) B cells of healthy individuals with wild-type or mutant (1858C/T) PTPN22.  For 
immature Igκ+ B cells, n=36 for WT, n=27 for mutant.  For mature Igκ+ B cells, n=39 
for WT, n=30 for mutant.  Among immature Igλ+ B cells, n=16 for WT, n=12 for 
mutant.  Among mature Igλ+ B cells, n= 18 for WT and n=17 for mutant.  All PCR 
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reactions were performed in duplicate.  (b) Differences in iRS rearrangement frequencies 
between immature and mature Igκ+ B cells tracked per individual.  Values from 
individuals with WT PTPN22 are depicted on the left (n=35) and those with mutant 






Figure 3-7: AEC mice display RS rearrangement levels equivalent to wild-type 
mice.  Vκ-RS rearrangement levels in genomic DNA from bone marrow (Fr. D, Fr. E, and 
Fr. F) and splenic (Fo, MZ, and IgM+) B cells of AEC mice (n=2, white bars).  Data from 
C57Bl/6 (black bars) and NOD (gray bars) mice are plotted for comparison.  All PCR 
reactions were performed in duplicate.  Data represent fold difference relative to the 






Rearrangement Model Precursor IF % IF Precursor 
Repertoire 
Prompt and Irreversible 
H/L-STOP 0% Not applicable 
“Leaky” H/L-STOP 33% Unrestricted 
Classical Editing 33%>…>0% Upper limit not defined* Autoreactive 
 
Table 1: Three models of receptor editing predict different frequencies of in-frame 
editing precursors.  In a model of complete feedback inhibition (prompt and 
irreversible H/L STOP), IgL rearrangement ceases with the expression of a function BCR 
on the cell surface irrespective of specificity.  Consequently, this model predicts that no 
editing precursors should be in-frame (IF).  In a model with incomplete (or the total 
absence of) feedback inhibition, IgL rearrangement may continue despite BCR surface 
expression.  Assuming IgL recombination results in an in-frame rearrangement 1/3 of 
the time, this model would predict 33% of editing precursors to be in-frame.  Moreover, 
if continued IgL rearrangement occurs without regard to BCR specificity, the specificity 
of IF editing precursors would be unbiased.  The classical model of receptor editing 
proposes that receptor editing occurs in response to autoreactivity.  Based upon this 
model up to 33% of editing precursors would be predicted to be IF, however, this model 
also predicts that IF precursors should encode for autoreactive light chains.  *Of note, 
the upper limit of IF frequency is variable, as it may be increased with positive selection 
for autoreactive receptors before editing or decreased with negative selection of B cells 













RP Vκ Seq. Jκ1 Seq. Frame 
24 12/J2 19-25 agc act cct   acg ttc ggt OF 
26 12/J2 12-41 agt act   tgg acg ttc ggt OF 




 100 12/J2 19-17 agt act cct   acg ttc ggt IF 
7 12/J2 bd2 cat ttt   tgg acg ttc ggt IF 
25 12/J5 21-3 gag gat cct   acg ttc ggt IF 
26 12/J2 21-2 gag gtt     acg ttc ggt OF 





 79 12/J2 8-24 agc act   tgg acg ttc ggt IF 
26 21D/J4 aq4 aac cca     acg ttc ggt OF 
40 21D/J2 8-19 agt tat   tgg acg ttc ggt OF 




 96 21D/J2 19-15 agc tat cct   acg ttc ggt OF 
 
 
Table 2: Nucleotide sequences at the junctions of inverted Vκ-Jκ1 rearrangements 
reveal several IF editing precursors.  Clones with Jκ inversions are defined as 
described in the text.  13 reciprocal products (RP) are presented, which were isolated 
from hybridomas derived from three different IgH transgenic strains hemizygous for Jκ-
Cκ deletion.  Listed are the hybridoma genotypes, clone number, editor Vκ gene 
expressed, and the identity of the Vκ gene present in the RP.  All the Vs/Jκ1inv PCR 












In these studies I explored the role of receptor editing in the context of 
autoimmune disease and investigated the stimuli responsible for promoting continued 
immunoglobulin light chain (IgL) recombination.  In Chapter 2, I described the 
development of a novel assay for monitoring tolerance in B cell populations.  The RS 
rearrangement assay measures a late receptor editing event involving the recombination 
of a non-coding gene segment in the Igκ locus, RS or recombining sequence, that 
results in the functional inactivation of Igκ.  Since RS does not code for a constituent of 
the BCR (Daitch et al. 1992), the RS rearrangement assay is not restricted to certain 
autoantigens and thus is broadly applicable to many autoimmune diseases.  
Additionally, the RS gene segment is also found in humans (called the kappa deleting 
element, KDE) (Siminovitch et al. 1985), thus it was easy to adapt the assay for use in 
human studies. 
Applying this assay I observed that B cells from mouse models of SLE (MRL/lpr) 
and T1D (NOD) harbored fewer RS rearrangements than wild-type mice (C57Bl/6), 
suggesting that defects in receptor editing may contribute to autoimmune disease.  
Interestingly, related mouse strains that develop less severe autoimmunity (MRL+/+, 
NOR) also showed evidence of decreased RS recombination, indicating that impaired 
receptor editing likely increases disease susceptibility but additional factors are involved 
in the development of more severe disease.  Additionally, the RS assay was used to 
characterize B cells from patients with SLE and T1D.  Approximately 30% of people from 
either disease group had lower RS levels than the 10th percentile of healthy individuals.  
This finding suggests that defects in receptor editing may also contribute to 
autoimmune disease in people.  Moreover, since some patients with autoimmune 
disease had relatively normal RS levels, the results also indicate heterogeneity among 
patients.  As the RS rearrangement assay measures the dominant mechanism of central 
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tolerance, this variability suggests differences in the efficacy of central tolerance in 
autoimmune patients, which may be relevant in treatment decisions. 
In Chapter 3 I explored the forces that may control antibody light chain receptor 
editing, including RS rearrangement.  Although increasing evidence suggests that 
receptor editing occurs in response to BCR autoreactivity of immature B cells (Hertz and 
Nemazee 1997; Halverson et al. 2004; Tze et al. 2005), conclusive demonstration of 
receptor editing induced by positive BCR signaling in vivo has been lacking.  Using IgH 
transgenic mice, I sought to correlate B cell autoreactivity with receptor editing.  Indeed, 
B cells expressing the anti-DNA IgH 56R underwent RS rearrangement more often than 
those expressing a wild-type IgH.  This mechanism was further explored through the 
characterization of editing precursors.  If autoreactivity stimulates receptor editing, then 
functional (in-frame) IgL rearrangements that have been edited should encode 
autoreactive light chains.  Analysis of editing precursors generated through RS and 
inversional Vκ rearrangement revealed a bias toward autoreactive light chains in multiple 
transgenic mouse strains, consistent with an autoreactivity-driven model of receptor 
editing. 
To further investigate if self-antigen induced positive signaling promotes 
receptor editing, I assessed the role of two BCR signaling components in RS 
recombination.  I found that lack of the inhibitory tyrosine kinase Lyn did not alter RS 
rearrangement levels.  Similarly, in human B cells a dysregulated isoform of the 
lymphoid phosphatase PTPN22, which is associated with autoimmune diseases including 
SLE and T1D (Bottini et al. 2004; Lee et al. 2007; Harley et al. 2008), did not adversely 
affect receptor editing.  Together these findings suggest that perturbation of these BCR 
signaling components alone do not affect receptor editing.  Additionally, to identify 
other factors that may be responsible for decreased RS rearrangement observed in the 
context of autoimmunity, receptor editing was examined in a mouse model of Sjögren’s 
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syndrome (AEC).  This mouse strain carries two of over twenty genetic loci correlated 
with type 1 diabetes in the NOD mouse.  However, unlike NOD mice, the AEC strain 
displayed RS rearrangement levels equivalent to wild-type mice, indicating that genes 
present on the two disease associated loci (Idd3 and 5) alone do not influence receptor 
editing.  Yet, this finding does not rule out the possibility that these loci act in concert 
with additional disease associated genes to influence receptor editing. 
 
FUTURE DIRECTIONS 
Development of RS Rearrangement as a Clinical Assay 
As described in Chapter 2, decreased RS rearrangement frequencies were 
detected in approximately 30% of patients with SLE and T1D suggesting that low RS 
levels may have prognostic value in determining the risk of developing autoimmune 
disease.  However several issues need to be addressed before the RS assay can be 
applied in this manner.  First, we need to determine how reproducible RS rearrangement 
levels are in individuals.  It may be possible that RS levels vary at different stages of 
autoimmune disease.  If B cells lacking RS rearrangements are involved in the 
pathogenesis of autoimmunity, these cells may be more prevalent during the early 
stages of disease process, possibly before the appearance of symptoms, as well as 
during disease flares.  Therefore it would be informative to measure RS levels at multiple 
time points in healthy individuals to define a baseline level of variability and then 
determine if RS levels change more in patients with autoimmune disease.  If RS 
rearrangement levels are found to be consistently lower in patients with autoimmune 
disease, it may be feasible to use the assay to predict an increased risk of developing 
autoimmune disease in undiagnosed individuals.  Studies comparing RS levels of 
siblings without disease to those with autoimmunity will also allow us to determine how 
closely RS levels correlate with autoimmune disease.  Furthermore, prospective studies 
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of individuals with average and low RS rearrangement levels would help define the 
relative risk of developing autoimmunity that low RS levels confer and demonstrate the 
possible prognostic value of the assay.  Finally, it would be interesting to see if RS 
rearrangement levels are similarly decreased in other autoimmune diseases such as 
rheumatoid arthritis and myasthenia gravis.  As the RS rearrangement assay is not 
dependent upon a specific autoantigen, it could easily be applied to assess central 
tolerance in these diseases. 
In addition to prognostic applications, the RS rearrangement assay may also be 
useful as a diagnostic tool.  As not all patients with autoimmune disease demonstrated 
decreased RS rearrangement frequencies, the RS assay has revealed heterogeneity 
among SLE and T1D patients that may have implications in treatment decisions.  
Decreased RS levels are suggestive of defects in central B cell tolerance, which is 
relevant to treatment since current therapies for SLE have included B cell depletion with 
rituximab (anti-CD20 mAb) (Leandro et al. 2002; Eisenberg 2006).  Rituximab is also 
being considered in immunosuppressive regimens used after islet cell transplant in T1D 
patients.  The premise behind use of this antibody in autoimmune disease treatment is 
to deplete the majority of circulating B cells (those that express CD20) with the hope 
that autoreactive B cells will also be eliminated and lead to remission or decreased 
severity of disease.  However, if a subset of patients generate autoreactive B cells due to 
defects in central tolerance, it is likely that such B cells will be generated again as the B 
cell repertoire is being reconstituted.  Moreover, under conditions of lymphopenia 
developing B cells may experience greater effective concentrations of pro-survival 
factors such as B lymphocyte stimulator (BLyS, also known as BAFF) that could result in 
impaired deletion of autoreactive B cells (Lesley et al. 2004; Thien et al. 2004).  Indeed, 
mice overexpressing BLyS develop lymphocytic expansions that share characteristics of 
autoimmune disease (Mackay et al. 1999).  Additionally, patients with SLE, rheumatoid 
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arthritis (RA), and Sjögren’s syndrome have been shown to have increased serum levels 
of BLyS (Cheema et al. 2001; Zhang et al. 2001).  Thus, B cell depletion in patients with 
central tolerance defects may in fact worsen their disease as the accompanying 
lymphopenia could foster the development and activation of newly generated 
autoreactive B cells.  Therefore the RS rearrangement assay may be useful in screening 
patients for defects in central tolerance and guiding their treatment. 
 
RS Rearrangement Assay Optimization 
Although it can be performed in less than 2 days, in its current form the RS 
rearrangement assay is not amenable to clinical use, as it requires FACS isolation of B 
cells and their separation based upon light chain isotype.  This separation is required 
due to the large differences in RS rearrangement levels between Igκ+ and Igλ+ B cells.  
However, if the RS levels could be reliably measured from whole blood genomic DNA it 
would shorten the time required and forego the need for FACS B cell isolation making 
the assay clinically viable.  Measuring RS rearrangements in whole blood is not 
completely straightforward, however, as inter-individual differences in the frequency of 
B cells and the κ:λ ratio can shift overall RS rearrangement levels significantly.  To 
compensate for this variability aliquots of blood samples could be analyzed by flow 
cytometry along with RS analysis to determine the B cell frequency and κ:λ ratio.  This 
information could then be used to calculate an individualized correction factor allowing 
RS levels to be compared between individuals. 
One caveat to this approach is that correction for the κ:λ ratio requires an 
assumed value of RS rearrangement in Igκ+ and Igλ+ B cells.  As we saw in Chapter 2, 
these values differ among individuals and more importantly they do not always change 
to the same degree.  For instance, an individual may have an average level of RS 
rearrangement among Igκ+ B cells, while Igλ+ B cells have lower than average RS levels.  
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One possibility to circumvent this problem would be to only focus on B cells of a single 
light chain isotype.  Given the increased RS rearrangement values in Igλ+, analyzing 
these cells would provide a greater dynamic range in which to detect differences.  Igλ+ B 
cells could be isolated from whole blood using magnetic bead separation, which may 
increase the time needed for RS analysis but still make it feasible in a clinical 
environment.  We are currently in the process of determining if this approach can 
provide accurate and reproducible measurement of RS rearrangement levels. 
 
Control of RS Recombination 
The studies described in this dissertation introduce a novel assay for estimating 
the degree of receptor editing in B cell populations through RS rearrangement levels, 
however, the mechanisms controlling RS recombination are unclear.  Although 
autoreactivity appears to be correlated with RS rearrangement, it is possible that other 
factors independently regulate RS recombination.  One possibility is that prolonged 
residence time of pre-B cells in the bone marrow leads to increased IgL rearrangement.  
Nussenzweig and colleagues observed that pre-B cells undergoing receptor editing 
experienced a 2-hour developmental delay (Casellas et al. 2001), which together with 
the finding that RS rearrangement occurs late in this process (Zou et al. 1993; Klein et 
al. 2005), suggests that B cells require increased time in the bone marrow to undergo 
extensive Igκ rearrangement.  This process has been described in T cell development, 
where absence of the nuclear receptor RORγ (retinoic acid receptor-related orphan 
receptor) causes a decrease in the lifespan of double positive (DP) T cells and a 
concomitant decrease in TCRα rearrangement (Guo et al. 2002).  Moreover, over-
expression of the anti-apoptotic gene Bcl-xL increased DP T cell lifespan and promoted 
use of downstream 3’ Jα gene segments, indicating that a survival window influences 
TCRα rearrangement. 
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Correspondingly, if the level of RS rearrangement is related to the time pre-B 
cells spend in bone marrow, conditions that extend this time may result in increased RS 
levels.  Indeed, expression of Bcl-xL in developing B cells increased RS rearrangement 
levels compared to wild-type, suggesting that a developmental window may function in 
a similar manner in B cells (Fig. 4-1).  Bone marrow residence time may also provide an 
alternative explanation for the increased RS rearrangement observed among anti-DNA 
(56R+) B cells (Fig. 3-1).  It may be possible that expression of the transgenic IgH leads 
to “premature entry” of early stage B cells into the pre-B cell compartment and, 
consequently, an extended window for IgL rearrangement.  To distinguish if 
autoreactivity or increased bone marrow residence time are responsible for increased RS 
rearrangement, it would be informative to measure RS levels from other IgH transgenic B 
cells with non-autoreactive B cell receptors.  Although the inability to screen for 
reactivity to all possible antigens makes determination of non-autoreactivity 
problematic, additional markers of non-autoreactivity, such as an unrestricted (wild-
type) IgL repertoire and normal peripheral B cell counts, may facilitate this 
determination.  Nevertheless, if these B cells also demonstrate higher RS levels, it would 
suggest that time in the bone marrow, rather than BCR specificity, controls RS 
rearrangement. 
Exploration of the pre-BCR signaling pathway has revealed several factors that 
promote IgL rearrangement (Fig. 1-2), which also could be involved in the regulation of 
RS recombination.  Recent reports have implicated the transcription factor Foxo1 in the 
upregulation of Rag required for IgL rearrangement (Amin and Schlissel 2008).  Through 
this activity, Foxo1 may also influence RS recombination, as this event appears to occur 
late in the process of IgL rearrangement and thus would require extended expression of 
Rag.  Nemazee and colleagues have proposed a model in which limiting levels of Rag in 
pre-B cells leads to the hierarchical pattern of IgL rearrangement, with Igκ rearranging 
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before RS and Igλ (Vela et al. 2008).  They propose that this restriction leads to 
competition among Rag substrates and that RS rearrangement occurs less frequently 
than Vκ rearrangement due to its sub-optimal recombination recognition sequence 
(RSS).  This non-canonical RSS may recruit Rag less efficiently and therefore compete 
poorly with Vκ gene segments that possess more favorable RSSs (Ramsden and Wu 
1991).  Thus, increased expression of Rag mediated by Foxo transcription factors may 
improve the chances of RS rearrangement.  Conversely decreased expression of Foxo1 
or its export from the nucleus due to Akt-mediated phosphorylation could lead to 
decreased RS recombination and in turn impaired receptor editing if functional Igκ 
chains cannot be silenced via RS rearrangement.  Measuring Foxo1 expression or 
phosphorylation in pre-B and immature B cells of mouse strains demonstrating 
decreased RS recombination would be informative in this regard.  If Foxo1 levels or 
activity are found to be correlated with RS recombination, the causality of this 
relationship could be explored by experimentally altering the expression of the 
transcription factor.  Specifically, Foxo1 expression could be decreased in immature 
56R+/+ B cells to determine if this results in impaired editing and moreover, if this 
deficiency could cause a loss of tolerance and development of autoimmune disease.  
Foxo1 knockdown could be achieved by introduction of Foxo1 specific shRNA into 
primary bone marrow B cells via ex vivo retroviral transduction (as described in (Amin 
and Schlissel 2008)).  Transduced B cells could then be introduced into irradiated hosts 
and RS rearrangement levels of the resulting mature peripheral B cells could be 
assessed.  Additionally, markers of autoimmunity, such as increased serum antibody 
titers and histological changes could be examined. 
Interferon regulatory factor 4 (IRF-4) has also been shown to be a critical 
mediator of pre-BCR signaling that serves to shut down pre-B cell proliferation and 
stimulate IgL rearrangement.  IRF-4 promotes Igκ rearrangement directly through 
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interactions with the 3’Eκ (Eisenbeis et al. 1995), as well as indirectly by enhancing E2A 
binding of the iEκ via downregulation of IL-7 signaling (Lazorchak et al. 2006; Johnson 
et al. 2008).  Recently Pathak et al. reported that IRF-4 might also be required for 
efficient receptor editing in response to membrane antigens (Pathak et al. 2008).  The 
authors found that IRF-4 deficient mice expressing a transgenic anti-HEL BCR failed to 
produce non-autoreactive B cells when exposed to membrane bound HEL (mHEL), 
suggesting that autoreactive B cells were largely deleted or anergized rather than 
tolerized via receptor editing.  The authors confirmed that IRF-4-/- pre-B cells 
underwent less RS and λ1 rearrangement compared to IRF-4 replete cells and found that 
IRF-4 transcription was induced by BCR ligation in immature B cells.  Taken together 
these findings support a role for IRF-4 in receptor editing and suggest that deficiencies 
in IRF-4 activity may contribute to decreases in RS rearrangement levels observed in 
autoimmune individuals.  Indeed, aberrant activity of IRF-4 in T cells is associated with 
development of rheumatoid arthritis and vasculitis (Chen et al. 2008).  Thus 
measurement of IRF-4 expression and its binding levels at the Igκ enhancers as 
determined by chromatin immunoprecipitation (ChIP) in pre-B cells of MRL/lpr and NOD 
mice may begin to address whether IRF-4 contributes to the development of their 
autoimmune disease.  Additionally, in concert with E2A, IRF-4 has been shown to 
increase histone acetylation and germline transcription of the Igκ locus (Lazorchak et al. 
2006).  Thus to further address potential aberrations in IRF-4 activity, histone 
acetylation at the Igκ locus can be examined by ChIP. 
Upstream of IRF-4 and Foxo1 in the signaling cascade, the scaffold protein SLP-
65 has also been implicated in stimulation of IgL rearrangement.  Loss of SLP-65 results 
in decreased Igκ germline transcription and rearrangement in pre-B cells (Hayashi et al. 
2003).  More importantly, SLP-65 deficiency also impairs receptor editing, as Kitamura 
and colleagues observed that SLP-65-/- mice expressing an anti-DNA BCR (3H9/Vκ4) fail 
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to rearrange endogenous Vκ genes or RS and generate fewer Igλ+ B cells (Hayashi et al. 
2004).  They also observed similar effects in mice with a wild-type BCR repertoire, 
indicating that SLP-65-mediated signaling is required for effective receptor editing.  As 
SLP-65 activates several additional signaling molecules, it is unclear from these studies 
if SLP-65 directly promotes receptor editing or if it acts indirectly through its binding 
partners.  Phospholipase Cγ2 (PLCγ2) is one such signaling enzyme downstream of SLP-
65 that has also been implicated in regulation of receptor editing (Wang et al. 2000; Bai 
et al. 2007).  Wang and coworkers found that autoreactive B cells from PLCγ2 deficient 
mice did not receptor edit appropriately based upon decreased Igλ surface expression 
and reduced endogenous Igκ and Igλ rearrangement.  Furthermore, these cells 
demonstrated impaired IRF-4 upregulation in response to BCR stimulation.  Together 
these findings suggest that SLP-65 or its binding partners may contribute to defects in 
receptor editing identified in Chapter 2.  To clarify the role of this signaling pathway in 
MRL/lpr and NOD mice, the tyrosine phosphorylation status of these molecules in pre-B 
cells could be measured and compared to those from murine strains that receptor edit 
appropriately.  Additionally, to test if impaired PLCγ2 activity is responsible for 
decreased editing, one could attempt to stimulate secondary rearrangements with 
ionomycin and phorbol 12-myristate 13-acetate (PMA) in order to activate protein 
kinase C (PKC), the main target of PLCγ2 activity. 
 
The Significance of Altered RS Recombination 
As discussed in Chapter 2, two different mouse models of autoimmune disease 
as well as a subset of humans with SLE and T1D demonstrated decreased levels of RS 
rearrangement, indicating impairment of receptor editing.  The commonality of 
decreased RS recombination among these individuals suggests that reduced editing may 
be a contributing factor to the development of autoimmune disease, however, the 
 104 
consequence of the production of minimally edited cells remains unclear.  An obvious 
question that arises from these findings is whether B cells lacking RS rearrangement 
tend to be more autoreactive.  In Chapter 3, we saw that in self-tolerant mice, B cells 
expressing an anti-DNA heavy chain, 56R, underwent increased RS rearrangement 
compared to B cells expressing endogenous heavy chains, suggesting that BCR 
specificity influences the degree of RS rearrangement.  Additionally, the prevailing 
model of receptor editing proposes that editing serves to mitigate autoreactivity of 
immature B cells so that peripheral B cells are largely non-autoreactive. 
However, this is not always the case as receptor editing can also lead to light 
chain allelic inclusion (expression of two different functional light chains) and B cell 
polyreactivity (Liu et al. 2005; Witsch et al. 2006; Casellas et al. 2007).  Due to 
intracellular antibody sequestration, IgL competition for IgH pairing, or partial 
autoreactivity (Liu et al. 2005; Doyle et al. 2006; Casellas et al. 2007), allelically included 
and polyreactive B cells may be able to bypass central tolerance mechanisms and 
participate in autoimmune responses.  This scenario suggests that rather than 
abrogating autoreactivity, increased receptor editing may in fact promote development 
of autoimmune disease. 
To determine whether B cells with increased or decreased editing levels 
participate in autoimmune responses, B cells specific for characteristic disease 
associated self-antigens could be examined.  These studies could be facilitated through 
the isolation of antigen-specific B cells.  For instance, serum anti-insulin antibodies are 
commonly found in patients with type-1 diabetes (Ziegler et al. 1991; Nakayama et al. 
2005).  Consequently, isolation and characterization of receptor editing levels of anti-
insulin B cells may help determine the significance of decreased RS recombination in 
affected individuals.  To determine if anti-insulin B cells could be identified by flow 
cytometry, I analyzed the insulin reactivity of 56R+/- splenocytes which have been shown 
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to recognize several auto-antigens, including insulin, based upon hybridoma studies of 
Igκ deficient 56R mice (Doyle et al. 2006).  Preliminary studies using tetrameric insulin 
to identify anti-insulin B cells indicate that this approach may be feasible (Fig. 4-2a).  
Additionally, it is possible that frankly autoreactive B cells develop differently than 
poly/multi-reactive B cells.  For example, autoreactive B cells may be generated with 
minimal receptor editing, while multireactive B cells may be allelically included 
secondary to extensive receptor editing.  Therefore identifying multireactive B cells via 
double antigen staining will allow separate characterization of autoreactive and 
multireactive B cells (Fig. 4-2b). 
If isolation of these B cells is possible, analysis of RS rearrangement levels and 
light chain allelic inclusion may provide evidence for different pathways of generating 
autoreactivity versus multireactivity.  Moreover, if also performed in the context of 
autoimmune disease, it will allow for the assessment of the function of included and/or 
multireactive B cells in the disease process and clarification of the role of receptor 
editing.  We may find that receptor editing is a double-edged sword, which as a whole 
functions to reduce autoreactivity, but can also provide a pathway for bypassing 







Figure 4-1: Bcl-xL expression increases Vκ-RS rearrangement levels in immature 
bone marrow B cells.  Vκ-RS rearrangement levels in genomic DNA from bone marrow 
(Fr. D, Fr. E Igκ+, and Fr. F Igκ+) B cells of Bcl-xL transgenic (n=3, gray bars).  Data from 
C57Bl/6 mice (n=5, black bars) are plotted for comparison.  All mice were 2-3 months 
of age.  All PCRs were performed in duplicate.  Data represent fold difference relative to 











Figure 4-2: Auto-antigen staining of C57Bl/6 and 56R+/- splenic B cells.  (a) Live (7-
AAD-) B220+ splenic lymphocytes from wild-type (left) and 56R+/- (middle) mice stained 
with 500ng insulin (total volume 100µL; pre-conjugated to SAv-FITC in a 4:1 ratio).  The 
histogram plot on the right depicts insulin staining of wild-type (red) and 56R+/- (blue) 
splenic marginal zone B cells (CD21+ CD23-).  (b) Live (7-AAD-) immature (B220+ 
AA4.1+, left) and mature (B220+ AA4.1-, right) splenic lymphocytes from wild-type (top) 
and 56R+/- (bottom) mice stained with 250ng insulin (pre-conjugated to SAv-FITC in a 












B6.56R mice have been described previously (Sekiguchi et al. 2006).  C57Bl/6, 
NOD, NOR, MRL/lpr, and MRL/MpJ mice were obtained from Jackson Laboratories.  AEC 
mice were originally a gift from Philip Cohen.  Bcl-xL mice have been previously 
described (Gonzalez-Garcia et al. 1994).  All animal experiments were performed on 3-
4 month old mice in accordance with protocols approved by the University of 
Pennsylvania School of Medicine Animal Care and Use Committee. 
 
Flow Cytometry 
Murine cell suspensions were prepared from femurs, tibias, and spleens in FACS 
buffer (PBS, 0.5% BSA, 0.01% NaN3, 1mM EDTA) following hypotonic RBC lysis (ACK 
Lysing Buffer, BioWhittaker).  B cell populations were defined as described in Figure 2-2.  
Due to poor reactivity of AA4.1 antibodies in NOD and NOR mice (Langmuir et al. 1993), 
bone marrow and peripheral subsets in these mice were defined using a method that 
has been described previously by others (Figure 2-2, (Quinn et al. 2006)).  Human B 
cells were isolated from whole blood using Lymphocyte Separation Medium (MP 
Biomedicals, Solon, OH) followed by resuspsension in FACS buffer.  Murine lymphocytes 
were stained using anti-IgM-PE-Cy7 (II/41), anti-IgD-PE (11-26), anti-B220-APC-
AF750 (RA3-6B2) (eBioscience), and anti-Igκ-FITC (187.1), anti-BP-1-FITC (6C3), anti-
CD43-PE (S7), anti-CD23-PE (B3B4), anti-AA4.1-APC,  (BD-Pharmigen).  Human 
lymphocytes were stained with anti-CD19-Pacific Blue (Caltag Laboratories) and anti-
Igλ-FITC, anti-CD27-FITC, anti-Igκ-PE, anti-CD38-PE-Cy7 (BD Pharmingen).  To 
maximize efficient use of patient samples for additional experiments not described 
here, CD19+ B cells marked by the anti-idiotypic monoclonal antibody 9G4, which 
recognizes VH4-34 heavy chain rearrangements (Isenberg et al. 1993), were excluded 
from human CD19+ B cell populations described herein (Figure 2-2d).  9G4Id+ cells 
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comprised 5.1%, 5.7%, and 4.2% of total CD19+ B cells from control, SLE, and T1D 




Genomic DNA was isolated from sorted B cells using the Gentra PureGene Tissue 
Kit (Qiagen).  Quantitative PCR (40°C 10 min., 95°C 10min., followed by 60 cycles at 
95°C 10 sec., 60°C 30 sec., 72°C 1 sec.) was performed on 15-50ng template DNA in a 
20µL reaction mix containing 1X LightCycler 480 Probes Master Mix (Roche Applied 
Science), 0.5U LightCycler Uracil-DNA Glycosylase (Roche Applied Science), 0.5µM 
forward primer, 0.5µM reverse primer, and 0.2µM hydrolysis probe using a LightCycler 
480 real-time PCR system (Roche Applied Science).  Vκ-RS rearrangements were 
amplified with 5'-GGCTGCAGSTTCAGTGGCAGTGGRTCWGGRAC-3' (Schlissel and Baltimore 
1989) and 5'-CTGAGCTCAACTGCAGTCCTA-3' primers and detected with 5'-
TGGCAGCCCAGGGTGGATCT-3’ FAM-labeled hydrolysis probe. For each sample, the 
intronic region of the reference control gene β-actin was amplified in a separate well 
with forward primer 5’-GAGGCTCTTTTCCAGCCTTC-3’ and reverse primer 5’- 
TCCATACCTAAGAGAAGAGTGACAGA-3’ and detected with a Cy5-labeled hydrolysis probe 
5'-AAGGTGACAAAACTCCTGAGGCCA-3'.  iRS-KDE rearrangements were amplified with 5’-
ATTGATGCTGCCGTAGCC-3’ and 5’-AGGCTTCCTAGGGAGGTCAG-3’ primers and detected 
with 5’-TCTGCAGCTGCATTTTTGCCA-3’ FAM-labeled hydrolysis probe.  Similarly, for each 
sample, the intronic region of the reference control gene β-actin was amplified in a 
separate well with forward primer 5’-CCCAGCACAATGAAGATCAA-3’ and reverse primer 
5’-AGTACTTGCGCTCAGGAGGA-3’ and detected with a Cy5-labeled hydrolysis probe 5’-
TGCCTGAGCTGACCTGGGCA-3’.  For Vκ-RS quantitation each product (Vκ-RS or β-actin) 
was analyzed by the standard curve method (titrated cloned Vκ-RS or NIH3T3 genomic 
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DNA, respectively) and the amount of Vκ-RS product in each mouse sample was then 
normalized to the amount of β-actin product.  Samples were compared to the 
normalized target value in wild-type C57Bl/6 B220+ IgM+ κ+ splenocytes to determine a 
relative quantity (comparative CT (DDCT) method).  The frequency of iRS-KDE 
rearrangements in each human sample was determined via absolute quantification using 
a standard curve generated by serial dilution of a cloned iRS-KDE rearrangement 
resuspended with 100ng human fibroblast DNA (Fig. 2-3).  To determine the number of 
genome copies, β-actin was measured via absolute quantification using a standard 
curve consisting of serially diluted human fibroblast DNA.  Reactions were performed in 
duplicate and samples with inconsistent replicates or β-actin cycle numbers greater than 
35 were excluded. 
 
Vκ-RS and iRS-KDE Standard Curve 
To generate standard curves for Vκ-RS and iRS-KDE quantitative PCR, Vκ-RS and 
iRS-KDE rearrangements were cloned from murine and human lymphocytes, 





The cloned iRS-KDE rearrangement sequence is as follows (primers shown in bold): 
5’ATTGATGCTGCCGTAGCCAGCTTTCCTGTTGAGTGGCAGCCCAGGGCGACTCCTCATGAGTCTGCAGCT
GCATTTTTGCCATATCCACTATTTGGAGTCTGACCTCCCTAGGAAGCCT 3’ 
Each plasmid was serially diluted 10-fold into Tris-EDTA buffer eight times 
beginning with concentrations of 2.5ng/µL.  Vκ-RS and iRS-KDE serial dilutions were 
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combined with NIH3T3 (mouse) and LM216 (human) fibroblast DNA, respectively, 
yielding final fibroblast DNA concentrations of 20ng/µL.  The number of RS 
rearrangement copies in each dilution was quantified using the respective plasmid 
molecular weight (Vκ-RS = 2609777 g/mol; iRS-KDE = 2583122 g/mol). 
 
Human Subjects 
Volunteer healthy adult subjects with no history of autoimmune disease, no 
active viral or bacterial infection, or current use of immunomodulatory or 
immunosuppressive drugs were recruited.  Women who were nursing, pregnant, or who 
were planning on becoming pregnant during the duration of this study were excluded.  
Adults with documented SLE (fulfilling the ARA criteria (Tan et al. 1982)) were recruited 
from the Rheumatology clinic at the Hospital of the University of Pennsylvania.   Blood 
draws from SLE patients receiving steroids were performed prior to their first morning 
dose.  T1D patients were recruited from the Rodebaugh Diabetes Center at the Hospital 
of the University of Pennsylvania.  Subjects were included if they had a clinical history 
compatible with autoimmune T1D, defined by insulin-dependence, the absence of 
obesity, and an age of onset < 40 years or > 40 years together with elevated levels of 
autoantibodies to GAD65.  Subjects meeting these criteria but presently receiving 
immunosuppression drugs to support a kidney, pancreas, or islet cell transplant were 
excluded.  The study protocol was approved by the Institutional Review Board of the 
University of Pennsylvania and all subjects gave their written informed consent to 
participate. 
 
RS Precursor Isolation 
RS editing precursors were PCR amplified (95°C 10min., followed by 45 cycles at 
95°C 10 sec., 60°C 30 sec., 72°C 30 sec.) using forward Vκ gene specific primers (Vκ12: 
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5’-CGAGCAAGTGAGAATATTTACAGTAATTTAGC-3’; Vκ38c: 5’-CTCATACATTACACATCTACAT 
TACAGCC-3’) or a forward degenerate Vκ primer (5'-GGCTGCAGSTTCAGTGGCAGTGGR 
TCWGGRAC-3') and an RS specific reverse primer (5'-CTGAGCTCAACTGCAGTCCTA-3').  
Amplifications were performed on 10ng total spleen genomic DNA in a 20µL reaction 
mix containing 1.25U Failsafe Taq Polymerase PCR Mix (Epicentre Biotechnologies), 1X 
Failsafe PCR Buffer D (Epicentre Biotechnologies), 1µM forward primer, 1µM reverse 
primer.  PCR products were visualized by agarose gel (1.0%) electrophoresis.  Target 
products of 1.5kbp were isolated using the QIAquick gel extraction kit (Qiagen) and 
cloned using the TA TOPO Cloning Kit (Invitrogen). 
 
Insulin Staining of Fresh Splenocytes for Flow Cytometric Analysis 
Insulin – FW: 5733.49 g/mol   Insulin-biotin – Sigma #I2258 
Biotin – FW: 244.31 g/mol 
Streptavidin – 13kDa = FW: 51677.34 g/mol 
FITC – FW: 389.38 g/mol    FITC-streptavidin – BD Pharmingen 
#554060 
 
Pre-conjugate insulin-bio and FITC-sAV in FACS Buffer on ice. 
 
FACS Buffer: 1L PBS + 0.5% BSA + 0.01% NaN3 (1mL 10%NaN3) 
 
Cell Staining 
1. Centrifuge cells at 1300rpm for 7 minutes at 4°C. 
2. Aspirate as much media as possible and add 250µL FACS buffer (when < 50x106 
cells) or 350µL FACS buffer (when ~ 100x106 cells) (i.e. enough FACS to allow for 
easy transfer of 1x106 cells to staining tubes). 
3. Transfer 1x106 cells into each compensation tube and 1x106 cells to each 
analysis tube. 
4. Add 2mL FACS buffer to each tube.  Centrifuge at 1300rpm for 5 minutes at 4°C. 
5. Aspirate supernatant and vortex tubes to break up the cell pellet.  Add Fc-block, 
vortex, and incubate on ice for 5 minutes. 
6. Add staining antibody mix and vortex to distribute mix. 
7. Combine insulin-biotin and SA-FITC in 100µL FACS buffer in ratios listed 
below. 
8. Incubate tubes in the dark on ice for 20 minutes. 
9. Add 2mL FACS buffer to the tubes to wash cells.  Centrifuge tubes at 1300rpm 
for 5 minutes at 4°C.  Aspirate supernatant and vortex tubes to resupend cells. 
10. Repeat wash as described in step 7. 
11. Aspirate supernatant and vortex tubes to break up the cell pellet.  Add 100µL to 
compensation tubes and add streptavidin staining mix or preconjugated 
insulin to analysis.  Vortex briefly to distribute mix. 
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12. Incubate tubes in the dark on ice for 20 minutes. 
13. Add 2mL FACS buffer to the tubes to wash cells.  Centrifuge tubes at 1300rpm 
for 5 minutes at 4°C.  Aspirate supernatant and vortex tubes to resupend cells. 
14. Repeat wash twice as described in step 11. 
15. Resuspend cells in 0.4ml FACS buffer. 
 
Insulin-biotin + SA-FITC (4:1) Preconjugated 
Tube Sample FITC PE 7-AAD PE-Cy7 APC 
#1 Spleen 
1000ng 
Splenocytes Insulin (1000ng) 
1.67x10-10mol insulin (5µL) 
4.175x10-11mol SA-FITC 
(4.355µL) 





Splenocytes Insulin (500ng) 
8.35x10-11mol insulin (2.5µL) 
2.09x10-11mol SA-FITC 
(2.178µL) 















Splenocytes Insulin (100ng) 
1.67x10-11mol insulin (0.5µL) 
4.175x10-12mol SA-FITC 
(0.436µL) 





Splenocytes Insulin (50ng) 
8.35x10-12mol insulin (0.25µL) 
2.09x10-12mol SA-FITC 
(0.218µL) 






Group comparisons for the mouse experiments were performed with a two-
tailed Student's t-test unless otherwise specified.  Group comparisons in human 
subjects were performed via one-way ANOVA followed by two-tailed Student’s t-test.  
Correlation analyses were performed by calculating Spearman’s rank correlation 
coefficients.  Categorical data (gender, race) comparisons were analyzed using Fisher’s 
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